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Abstract
Patients with rheumatoid arthritis (RA) have premature mortality, which is mostly attributed to
cardiovascular diseases (CVDs), infections, gastrointestinal (GI) disorders, and RA itself. Some
studies report an increased death rate due to lymphoproliferative malignancies (LPMs). Studies on
changes in causes of death (CoDs) over time are scarce. One such study reported a decrease in
mortality between 1950 and 1981 due to RA, another study a decrease from 1980 to 1997 due to
myocardial infarction. The CoDs are nowadays only infrequently verified by autopsy, although
autopsy is regarded as the gold standard for determination of CoD. This study aimed to evaluate
determinants of mortality in RA patients. The study examined the CoDs over time. The study
addresses an autopsy population of RA patients, with non-RA patients serving as reference cases. In
the autopsied patients, the study evaluates CoDs over several decades, the contribution of autopsy to
the CoD determination, the contribution of RA medication to the CoDs, and the detection rate of
reactive systemic amyloid A (AA) amyloidosis at autopsy.
CoDs were studied in 960 RA patients who had been treated at the Kivelä Municipal Hospital in
Helsinki and who had died between 1971 and 1991 (Study population A). CoDs were then
evaluated in 369 consecutively autopsied RA patients and their reference cases without any
rheumatic disease (non-RA) of the same age at death, sex, and year of autopsy from 1952 to 1991
(Study population B). These autopsied patients had also been treated at Kivelä Hospital. To evaluate
the contribution of autopsy, CoD assessed by the clinician before autopsy and those determined by
the pathologist at autopsy were compared in autopsied RA patients and controls. For each patient,
death certificate data were reviewed. The CoD evaluation was based on multiple CoDs, including
immediate, underlying, and contributory causes. Furthermore, an intervening antecedent CoD was
also analysed when available. In autopsied patients, CoD determination was based on autopsy
findings. For the RA patients in Study population B, medical records between 1973 and 1991 were
available for analysis of clinical data. To evaluate the ultimate prevalence of amyloidosis, autopsy
tissue samples, 90% of which were available, were re-examined systematically. The detection rate
of reactive amyloidosis was studied by examining the prevalence of amyloidosis at the following
three levels: 1) during the course of RA, 2) at routine examination during autopsy, and 3) at
systematic re-examination of autopsy tissue samples.
In Study population A, the leading CoDs were CVDs, RA, and infections. From 1971 to 1991,
deaths caused by RA and renal disorders decreased, but no major change occurred in coronary
deaths.
In Study population B, the leading CoDs were RA, CVDs, and infections. In these patients,
deaths caused by RA also decreased from 1952 to 1991. Over the 40-year period, coronary deaths in
RA patients increased, but non-RA patients experienced a decrease in coronary deaths starting in
the 1970s. Between clinician-assigned diagnoses of CoD and those determined by the pathologist,
RA patients had lower agreement than non-RA patients regarding CVDs (Kappa reliability
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measure: 0.31 vs. 0.51) and coronary deaths (0.33 vs. 0.46). In both RA and non-RA patients,
malignancies were diagnosed most accurately during the lifetime. For patients treated at any time
during RA with disease-modifying anti-rheumatic drugs (DMARDs) and those without (Study
population B), autopsy-based CoDs were similar.
In Study population B, amyloidosis caused death in 10% of the RA patients, but in none of the
non-RA cases. Of the RA patients and those without RA (total of 739 patients), 90% of autopsy
tissue samples were available for re-examination. The re-examination for reactive amyloidosis
showed doubling of the prevalence of amyloid compared with the original autopsy reports: from
18% to 30% in RA and from 2% to 4% in non-RA patients. Prevalence of amyloid deposits at re-
examination showed no major change over time. In RA patients with amyloid at re-examination,
amyloidosis had been diagnosed before autopsy in only 37%, and these patients had a higher level
of inflammation during the course of RA, a longer duration of RA, and more disabling RA than RA
patients without amyloid. Of RA patients with amyloid, only half were known to have renal failure
or proteinuria or both.
In conclusion, the leading CoDs in RA patients were CVDs, RA, and infections. Deaths caused
by RA seemed to be decreasing. This appeared not to be true for coronary deaths. Despite advances
in diagnostic technology, autopsy remains an important tool in CoD determination. Coronary death
being less accurately diagnosed in RA patients may indicate that coronary heart disease (CHD) in
RA patients often remains unrecognized during lifetime. Thus, an active search for CHD and its
effective treatment is important to reduce cardiovascular mortality. Reactive amyloidosis appears to
be common, but is frequently undetected. Not only in RA patients with proteinuria or renal failure
or both, but also in those with active, long-lasting, and disabling RA, a systematic search for
amyloid is important to enable early diagnosis of amyloidosis, which will require effective
suppression of inflammation. Early enhancement of immunosuppressive therapy, including
biologicals in persistent active disease, is critical in preventing clinical manifestations of
amyloidosis, such as renal failure, which has a poor prognosis.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 0.5-1% of
populations worldwide. Development of RA is based on both genetic susceptibility and
environmental factors. Exposure to an infection may act as a trigger for RA (Silman and Pearson,
2002). The major basic manifestation of RA is joint involvement, which if ineffectively treated, will
eventually lead to disability. Inflammation in RA may occasionally affect extra-articular sites, such
as the pericardium or the pleura, as well as the vasculature. Furthermore, long-standing
inflammation in RA may cause deposition of amyloid fibrils in the extra-cellular space, leading to
the development of reactive systemic amyloid A (AA) amyloidosis. Reactive amyloidosis
frequently manifests as proteinuria and later as renal failure with a poor prognosis.
RA is associated not only with functional disability, but also with premature mortality (Kvien,
2004), known since 1953 (Cobb S et al., 1953). The increased mortality is mostly attributed to
cardiovascular diseases (CVDs) (Wolfe et al., 1994; Symmons et al., 1998; Goodson et al., 2005).
Infections (Symmons et al., 1998; Sihvonen et al., 2004a), especially infections of the respiratory
tract (Mutru et al., 1985; Sihvonen et al., 2004a) and urogenital tract (Vandenbroucke et al., 1984),
are also important determinants of mortality.  Mortality in RA is increased due to gastrointestinal
(GI) disorders and RA itself (Wolfe et al., 1994) as well as to reactive amyloidosis associated with
RA (Laakso et al., 1986a). Some studies have also found increased mortality due to
lymphoproliferative malignancies (LPMs) (Wolfe et al., 1994; Symmons et al., 1998).
Controversial reports on RA patients have emerged with respect to mortality changes over time.
During the period from 1964 to 1995, one series suggested the overall mortality rate in Swedish RA
patients to decline (Björnådal et al., 2002), but another series on US patients covering a longer
period from 1965 to 2005 indicated no improvement in survival (Gonzalez et al., 2007). In cause-
specific mortality, very few studies have reported changes over time. In mortality due to RA, an
Australian study from the 1950s to the 1980s (Wicks et al., 1988) and a French study from the
1970s to the 1990s (Ziade et al., 2008) showed a significant decline. However, French study
covering the period 1970 to 2002 demonstrated that deaths due to RA showed, starting in the mid–
1990s, a small rise (Ziade et al., 2008). From 1980 to 1997, a US series revealed mortality due to
myocardial infarction to decline (Krishnan et al., 2004). On the other hand, some studies have
observed no significant changes in cause-specific mortality (Suzuki et al., 1994; Björnådal et al.,
2002). However, only one of these series (Suzuki et al., 1994) was based on autopsied patients. In
that series, the autopsy rate of all deceased patients was 58%. In all other longitudinal series,
autopsy rates were unreported.
In follow-up studies, cause-of-death (CoD) information may be biased, because all RA patients
in such studies are not followed throughout their lifespan. For those patients alive at the end of the
study, information about CoDs remains unknown. CoDs vary with RA duration. Mortality risk at
least for infections, renal failure, and non-Hodgkin lymphoma rises with RA duration (Symmons et
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al., 1998). Furthermore, CoDs are only infrequently verified by autopsy, although clinically
determined CoDs without verification by autopsy may be inaccurate (Roulson et al., 2005).
Several studies on RA patients have shown a highly variable prevalence of reactive amyloidosis.
In biopsies taken from various sites during lifetime, the prevalence of amyloidosis has ranged from
7% to 19% (Kobayashi et al., 1996; Gomez-Casanovas et al., 2001; El Mansoury et al., 2002;
Kuroda et al., 2002; Ishii et al., 2003), and further 78% (Barile et al., 1993). At autopsy, amyloid
has been detected in 7% to 61% of the RA cases (Teilum and Lindahl, 1954; Ramirez et al., 1981;
Boers et al., 1987; Suzuki et al., 1994). Similarly, mortality rates due to amyloidosis have been
variable, ranging from 2% to 24% of RA patients (Mutru et al., 1976; Prior et al., 1984; Laakso et
al., 1986a; Lehtinen and Isomäki, 1991; Suzuki et al., 1994; Kvalvik et al., 2000; Martinez et al.,
2001). These highly variable figures evidently depend on the different patient populations and
search methods, but it is also likely that amyloid in some patients goes undetected.
This study aimes to elucidate determinants of RA mortality by investigating CoDs over a 21-
year period. The study then addresses an autopsy population of RA patients and their reference
cases. In these patients, the study evaluates CoDs over 40 years, the contribution of autopsy to the
CoD determination, the contribution of RA medication in relation to CoDs, and the detection rate of
reactive AA amyloidosis.
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2. Review of the literature
2.1 History of rheumatoid arthritis
History of rheumatic conditions can be investigated by analysing skeletons from archaeological
sites (Rothschild, 1995). Studying mummies by medical imaging, such as the Peruvian mummy
Rascar Capac by computed tomographic scan imaging (Appelboom and Struyven, 1999), also
provides information about the history of diseases affecting bones. In addition, art and historical
texts may provide insights into the origin of RA (Appelboom, 2004). In several of his paintings,
Rubens painted finger and wrist deformities resembling RA, and, in fact, he may have been one of
the first victims of an epidemic of RA starting in the 16th or 17th century (Appelboom, 2005). RA
is believed to have infiltrated to Europe from North America after Columbus had discovered the
New World. According to this theory, the sailors bought RA to Europe, when they returned home
from America. In the pre-Columbian era, no reports of RA had emerged in Europe (Rothschild,
2001). American Indians have even nowadays a high prevalence of RA (Silman and Pearson, 2002).
In European skeletons originating from pre-Columbian times, the findings resembling past arthritis
have most likely been conditions other than RA, i.e. gout or spondylarthropathy, which may have
originated from ancient Egypt (Appelboom and Russell, 2003).
2.2 Epidemiology of rheumatoid arthritis
In various populations, the prevalence of RA is approximately 0.5 - 1%, with the exception of
American Indians, who demonstrate a higher prevalence ranging from 5% to 7% (Silman and
Pearson, 2002). Nowadays, 25 - 50 persons of a population of 100 000 will annually develop typical
RA (Uhlig and Kvien, 2005; Kaipiainen-Seppänen and Kautiainen, 2006). Studies have reported the
prevalence of RA (Jacobsson et al., 1994), at least in female patients (Symmons et al., 2002), and
the incidence of RA (Jacobsson et al., 1994; Doran et al., 2002), at least that of rheumatoid factor–
positive RA (Kaipiainen-Seppänen and Kautiainen, 2006), to be declining. These findings should,
however, be interpreted with caution because of the varying methodologies used in classification of
RA (Uhlig and Kvien, 2005). However, the course of disease activity in RA patients has been
suggested to become milder in recent years in parallel with more active treatment strategies
(Welsing et al., 2005).
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2.3 Mortality in rheumatoid arthritis
RA is not only a debilitating disease, but it is also associated with premature mortality. Mortality
increases in parallel with duration of RA (Wolfe et al., 1994). Compared with the general
population, mortality in RA patients in clinical studies has increased up to 3-fold (Table 1). In
population-based studies, mortality in RA patients has been less marked (Table 2). Despite the
suggestion that disease activity in RA may have become milder over time, mortality has remained
high (Welsing et al., 2005). During recent years, the mortality gap between RA patients and the
general population has become even wider (Gonzalez et al., 2007). However, it is only recently that
reports have emerged offering explanations for this premature death (Naz and Symmons, 2007).
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Young, 2007 UK 1986-97 1429 459 1.27 22 9
Carmona, 2007 Spain B:2001-6,
E:1999-2005





ARAMIS = Arthritis, Rheumatism, and Aging Medical Information; B=BIOBADASER= Spanish register for RA patients treated with anti-tumour
necrosis factor (TNF) alpha therapy; E=EMECAR= Spanish register for RA patients to monitor clinical expression, disease activity and progression
of RA, and comorbidity; System; f=female; m=male; NA=not available; SMR=standardized mortality rate; asame study population; bsame study
population; call patients started methotrexate.
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NA=not available; NOAR=Norfolk arthritis register; a primary care-based inception cohort of patients with inflammatory polyarthritis;
SMR=standardized mortality rate; asame inception cohort of residents with RA in Rochester, Minnesota.
2.3.1 Predictors of premature mortality
In RA patients, several factors predict mortality. Premature mortality, as well as susceptibility for
developing RA, is linked to human leukocyte antigen (HLA)-DRB1 alleles located in the major
histocompatibility complex (MHC) of chromosome 6. HLA-DRB1 alleles share amino acid
homology, which has been the basis of the so-called shared epitope (SE) hypothesis, in which these
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DRB1 molecules bind an RA-inducing peptide(s) (Gregersen et al., 1987; de Vries et al., 2005). The
HLA-DRB1 SE genes have been associated not only with increased overall mortality (Farragher et
al., 2008), but also with increased mortality due to specific causes such as CVDs (Gonzalez-Gay et
al., 2007; Mattey et al., 2007b; Farragher et al., 2008) and malignancies (Mattey et al., 2007b).
Soluble tumour necrosis factor receptor II (sTNFRII) has been linked in RA patients to
increased mortality. Elevated levels of sTNFR II are particularly associated with mortality due to
CVDs, and these may be used for identifying patients at risk for premature death (Mattey et al.,
2007a).
Cigarette smoking has a clear causal connection to development of RA (Symmons et al., 1997).
This connection has been reported in seropositive RA (Stolt et al., 2003), especially in men
(Heliövaara et al., 1993; Uhlig et al., 1999; Albano et al., 2001). Cigarette smoking also seems to
have a negative impact on survival (Goodson et al., 2008a). Low education level (Leigh and Fries,
1991; Wolfe et al., 1994; Wållberg-Jonsson et al., 1999; Pincus et al., 2004; Young et al., 2007) or
never married (Leigh and Fries, 1991)  have also been associated with increased mortality.
HLA-DRB1 SE alleles have been shown to be exclusively associated with RA patients who are
positive for anti-citrullinated peptide antibodies (ACPAs) (Huizinga et al., 2005). In Finnish RA
patients, high titres of ACPA have predicted mortality (Sihvonen et al., 2005). The combination of
ACPA, smoking, and SE is especially associated with a high risk of premature death (Farragher et
al., 2008).
In RA patients, rheumatoid factor (RF) positivity is a predictor of early death (Mitchell et al.,
1986; Jacobsson et al., 1993; van Schaardenburg et al., 1993; Wolfe et al., 1994; Heliövaara et al.,
1995; Goodson et al., 2002; Mikuls et al., 2002; Sihvonen et al., 2005; Farragher et al., 2007;
Young et al., 2007). After adjusting for age, sex, and smoking, RF positivity predicts mortality also
in persons with no arthritis (Heliövaara et al., 1995). In RA patients (Goodson et al., 2002;
Gonzalez et al., 2008b) as well as in a randomly selected population (Aho et al., 1982),
seropositivity for RF was linked to excess cardiovascular mortality.
As in the general population, premature mortality in the RA population is strongly predicted by
male gender (Mitchell et al., 1986; Leigh and Fries, 1991; Jacobsson et al., 1993; Wolfe et al., 1994;
Young et al., 2007). In RA patients with disease onset at an older age, i.e. > 60 years, RA seems to
have a more severe course, as measured by disease activity and radiographic damage (van der
Heijde et al., 1991). Parallel with this observation, age in RA patients, expressed as an odds ratio,
has proven to be a predictor of mortality (Chehata et al., 2001; Young et al., 2007).
Persistently active RA predicts early mortality (Reilly et al., 1990; Wolfe et al., 1994; Chehata et
al., 2001; Farragher et al., 2007). Active inflammation in RA seems to be associated with premature
cardiovascular death. In RA patients positive for RF, a high erythrocyte sedimentation rate (ESR)
predicted overall mortality as well as the risk for development of CVD (Wållberg-Jonsson et al.,
1999). This study also observed that DMARD therapy was associated with decreased mortality risk.
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In patients with recent onset inflammatory polyarthritis, baseline serum C-reactive protein (CRP)
was an independent predictor of subsequent death due to CVD (Goodson et al., 2005). A
population-based study on Pima Indians showed joint swelling, independent of other known risk
factors, including RA, to be a risk factor for CVD-related death (Jacobsson et al., 2001). Because
traditional risk factors, such as tobacco smoking and dyslipidemia, incompletely explain accelerated
atherosclerosis in RA patients, systemic inflammation associated with RA may play an important
role (Van Doornum et al., 2002).
In RA patients (Leigh and Fries, 1991; Wolfe et al., 2003; Sokka et al., 2004; Farragher et al.,
2007; Young et al., 2007) and also in the general population (Sokka et al., 2004), functional
disability measured by the Health Assessment Questionnaire (HAQ) is a strong predictor of
premature mortality. In RA patients, HAQ has been an important independent predictor also of
increased cardiovascular mortality (Farragher et al., 2007). Furthermore, physical measures of
functional status, such as grip strength, walking time, and button test, predict untimely overall
mortality (Pincus, 2005). These tests, unlike patient questionnaires, bypass socio-cultural
differences, the effect of which can be seen if patient questionnaires are used (Pincus, 2005). One
advantage in the use of patient questionnaires is that they involve less professional time (Pincus,
2005).
Excess mortality in RA patients is strongly associated with occurrence of extra-articular
manifestations (Erhardt et al., 1989; Turesson et al., 2002; Gabriel et al., 2003, Young et al., 2007).
Poor prognosis is predicted especially by vasculitis, pericarditis, pleuritis, and Felty’s syndrome
(Turesson et al., 2002). Furthermore, rheumatic nodules have been linked to increased overall
mortality (Wolfe et al., 1994; Chehata et al., 2001) as well as to increased cardiovascular mortality
(Naz et al., 2008). Extra-articular features or vascular inflammation have been suggested to identify
RA patients at particularly high cardiovascular risk (Naz et al., 2008).
2.3.2 Causes of death
Several RA mortality studies have shown an increased death rate due to CVDs, infections, GI
disorders, and LPMs (Table 3).
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Young, 2007 NA 1.5b 1.1 6.8 1.1c 2.4 0.9
Established cohorts
Linos, 1980 NA 1.0b 1.4 NA 0.8 NA NA
Allebeck, 1982 NA 1.5 1.1 3.6 1.1 NA 4.1
Vandenbroucke, 1984 0.9 NA NA 3.7 0.7 NA NA
Prior, 1984 2.4 NA NA 11.1 1.6 NA 6.5
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Kvalvik, 2000 1.3 NA NA NA 1.6 NA NA



























Cardiovascular diseases include cardiac and cerebrovascular diseases; cardiac diseases include all cardiac diseases and disorders of vessels, but
exclude cerebrovascular diseases; BIOBADASER= Spanish register for RA patients treated with anti-tumour necrosis factor (TNF) alpha therapy;
EMECAR= Spanish register for RA patients to monitor clinical expression, disease activity and progression of disease, and co-morbidity (a few RA
patients received TNF alpha therapy); GI=gastrointestinal disorders; LPMs=lymphoproliferative malignancies; NA=not available; adetermination of
infection varies; bcoronary heart disease; csolid tumours; dnon-Hodgkin lymphoma.
18
2.3.2.1 Cardiovascular diseases
In several RA mortality studies, CVDs have been the leading CoD (Wållberg-Jonsson et al., 1997;
Symmons et al., 1998; Kvalvik et al., 2000; Björnådal et al., 2002; Goodson et al., 2002; Sihvonen
et al., 2004a; Goodson et al., 2005). However, some studies have observed, compared with the
general population (Sokka et al., 1999) or reference cases without RA (Riise et al., 2001b), no
increased death rate due to CVDs. This is true especially for the RA mortality studies published
before the 1990s (Cobb S et al., 1953; Davis and Engleman, 1974; Mutru et al., 1976;
Vandenbroucke et al., 1984). Of cardiovascular deaths, the majority are caused by coronary heart
disease (CHD) (Björnådal et al., 2002; Sihvonen et al., 2004a). One of the early studies reporting
that RA patients die less frequently than their controls due to CHD suggested acetylsalicylic acid
(ASA) to have had a protective effect against coronary events (Davis and Engleman, 1974).
A meta-analysis of RA mortality studies (case-control and cohort studies) covering the period up
to 2005 reported increased mortality due to CHD and cerebrovascular diseases (Avina-Zubieta et
al., 2008). Furthermore, another meta-analysis on RA (case-control and cohort studies) covering the
period up to 2006 made similar observations, but stated that the incidence of fatal cerebrovascular
accidents was three times less than that of myocardial infarction (Levy et al., 2008).
Several studies on RA have linked together, even in pre-menopausal female RA patients (Pahor
et al., 2006), active inflammation and accelerated atherosclerosis. Accelerated atherosclerosis is
suggested to be an important contributor in RA patients to their increased cardiovascular mortality.
RA patients are also susceptible to dyslipidemia. Inflammation leads to pro-atherogenic changes in
lipoproteins (Nurmohamed, 2007). RA patients are at risk for unrecognized CHD and sudden
cardiac death (Maradit-Kremers et al., 2005b). Furthermore, RA patients are susceptible to atypical
presentation of acute coronary syndrome (ACS) and have, compared with the general population,
worse outcome (Douglas et al., 2006). After ACS, RA patients seem to more frequently experience
recurrent ischaemic events and death (Douglas et al., 2006). RA patients also die frequently of heart
failure (Mutru et al., 1989). In RA patients, congestive heart failure, rather than CHD, has been
suggested to be an important contributor to the excess mortality (Nicola et al., 2006).
2.3.2.2 Rheumatoid arthritis
Mortality in RA patients is frequently attributed to RA itself (Allebeck, 1982; Vandenbroucke et al.,
1984; Wolfe et al., 1994). However, on death certificates it remains frequently underreported
(Allebeck et al., 1981, Laakso et al., 1986c). RA as a CoD may appear alone or with various
associated complications. Pericarditis is a common extra-articular manifestation of RA, but it is
only rarely life-threatening (Voskuyl, 2006). On the other hand, mortality appears to be excessive in
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patients with an active vasculitic process (Erhardt et al., 1989). Pulmonary fibrosis in association
with RA is also linked with excess mortality (Young et al., 2007). Furthermore, medullar
compression in the cervical spine may be life-threatening (Sunahara et al., 1997; Riise et al.,
2001a). This complication may develop as early as two years after the onset of RA, although it
usually develops much later (Weissman et al., 1982). Cervical spine disorders are frequently
underestimated as a CoD (Neva et al., 2001). Since neurological symptoms correlate with autopsy
findings in the cervical spine only weakly, atlantoaxial dislocation may remain undetected during
the lifetime (Mikulowski et al., 1975).
2.3.2.3 Reactive amyloidosis
Reactive systemic AA amyloidosis associated with RA is an important determinant of mortality.
High inflammatory activity, including high level of serum amyloid A (SAA), in RA is associated
with development of reactive amyloidosis (Tiitinen et al., 1993). With continuous active
inflammation, the amyloid load increases (Gillmore et al., 2001). Furthermore, the more extensive
the amyloid deposition, the higher the risk of clinical manifestations (Kobayashi et al., 1996). Renal
amyloidosis frequently manifests with clinical signs and symptoms (Wright and Calkins, 1981;
Browning et al., 1985; Husby, 1992; Lachmann et al., 2007), but clinical manifestations are rare
with cardiac involvement (Wright and Calkins, 1981; Browning et al., 1985; Husby, 1992).
Amyloidosis may also lead to GI disturbances such as malabsorption (Pettersson and Wegelius,
1972) and diarrhoea (Okuda et al., 1997). In association with amyloidosis, appearance of intractable
diarrhoea (Okuda et al., 1997) or renal failure (Cohen and Comerford, 1968; Gertz and Kyle, 1991)
is a sign of a poor prognosis. Amyloidosis associated with RA has been estimated to shorten the
lifespan by eight years (Myllykangas-Luosujärvi et al., 1999).
In the literature, the prevalence of reactive amyloidosis associated with RA (Table 4) as well as
mortality due to amyloidosis (Table 5) varies highly. This variation may arise from different study
populations and diagnostic procedures. Techniques for detecting amyloid deposits may differ in
sensitivity. Fine-needle aspiration biopsy of subcutaneous fat is the preferred method for screening
and diagnosing reactive amyloidosis because it is convenient and safe (Westermark and Stenkvist,
1973; Klemi et al., 1987). However, this technique seems to be more insensitive than rectal (Klemi
et al., 1987; Dhillon et al., 1989) or gastroduodenal (Kuroda et al., 2002) biopsies.
Autopsy is regarded, at least in CoD determination, as the gold standard (Goldman et al., 1983;
Welsh and Kaplan, 1998). Studies reporting detection rates of amyloid during the lifetime compared
with autopsy findings are scarce. Such studies have comprised small populations of 21 patients or
fewer. One of these studies reported pre-mortem detection rate of amyloidosis in RA to be as high
as 81% at an amyloid clinic (Browning et al., 1985). In another study, amyloidosis was diagnosed
before autopsy in one-third of patients with chronic inflammatory disease (Wright and Calkins,
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1981). In one early study, less than one-tenth of cases with moderate to severe amyloid deposition
were diagnosed before autopsy as having amyloidosis (Teilum and Lindahl, 1954).











Teilum, 1954a Denmark NA 28 17 (61) Autopsy Systematic
Arapakis, 1963 UK NA 115 6 (5) Rectal biopsy Consecutive;
hospitalized
patients
Lender, 1972 Israel NA 54 6 (11) Rectal biopsy Hospitalized
patients
Ramirez, 1981 USA 1965-77 76 6 (8) Autopsy Consecutive
autopsies
Boers, 1987b NL 1958-84 132 14 (11) Autopsy Consecutive
autopsies
Tiitinen, 1993 Finland 1973-75 102 11 (11) SFA Cohort of ERA
patients examined
systematically





Suzuki, 1994c Japan 1960-90 81 17 (21) Autopsy Consecutive
autopsies
Helin, 1995 Finland 1976-92 110 33 (30) Renal biopsy Renal diseased
Kobayashi, 1996 Japan 1989-91 407 54 (13) GI biopsy RA patients
attending hospital
Nakano, 1998 Japan 1979-96 158 30 (19) Renal biopsy Renal diseased
Gomez-Casanovas,
2001
Spain 1983-98 313 61 (20) SFA Routine
screening; RA>5
years
El Mansoury, 2002 Egypt Jan, 1999-Aug
1999
















Kuroda, 2002 Japan 1988-95 1006 71 (7) GI biopsy Consecutive
inpatients
Ishii, 2003 Japan NA 217 17 (8) SFA RA>5 years
Wakhlu, 2003 India NA 113 30 (27) SFA RA>5 years
Wiland, 2004 Poland 1996-2001 121 35 (29) SFA RA patients
attending hospital
Calguneri, 2006 Turkey 1988-2003 526 6 (1) NA Retrospective
survey of medical
records
ERA=early rheumatoid arthritis, not more than 6 months; GI=gastrointestinal; NA=not available; NL=the Netherlands; SFA=subcutaneous fat
aspiration; atwo cases with ankylosing spondylitis and the rest with RA; bonly kidneys examined, autopsy rate 70%; cautopsy rate 58% in RA cases;
durinary abnormalities or renal dysfunction or both.














Mutru, 1976 Finland 1959-74 41 41 7 (17) NA NA Autopsy
Prior, 1984 UK 1964-78 448 199 3 (2) NA 11 Clinical
Laakso, 1986a Finland 1959-68 1000 356 31 (9) 32 10 Clinical
Reilly, 1990 UK NA 100 63 4 (6) 30 25 Clinical
Lehtinen, 1991 Finland 1961-66 573 251 61 (24) NA 23-28 Clinical
Suzuki, 1994 Japan 1960-90 81 81 6 (7) 58 NA Autopsy
Myllykangas-
Luosujärvi, 1999
Finland 1989 1666 1666 97 (6) 27 Cross-
sectional
Community
Kvalvik, 2000 Norway 1977 147 68 4 (7) a NA 16 Clinical
Martinez, 2001 Spain 1989 182 23 4 (17) NA 9 Clinical
Sihvonen, 2004a Finland 1988 1042 384 28 (7) 32 12 Community
aData from 60 patients available for analysis
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2.3.2.4 Infections
Mortality in RA patients is increased due to infections (Allebeck, 1982; Prior et al., 1984;
Vandenbroucke et al., 1984; Mutru et al., 1985; Wolfe et al., 1994; Symmons et al., 1998; Sokka et
al., 1999), especially of the respiratory (Prior et al., 1984; Vandenbroucke et al., 1984; Mutru et al.,
1985; Thomas et al., 2003) and urogenital (Vandenbroucke et al., 1984)   tracts. The risk of
infectious deaths increases in parallel with RA duration (Symmons et al., 1998). Of infectious
deaths, the majority are constituted by respiratory infections (Mutru et al., 1976; Suzuki et al.,
1994). Male sex and increasing age seem to predispose to respiratory tract infections (Coyne et al.,
2007).
2.3.2.5 Malignancies
Excess mortality in RA patients is attributed to LPMs (Laakso et al., 1986b; Wolfe et al., 1994;
Myllykangas-Luosujärvi et al., 1995a; Symmons et al., 1998; Thomas et al., 2003; Sihvonen et al.,
2004a). The mortality risk for LPMs increases with RA duration (Myllykangas-Luosujärvi et al.,
1995a; Symmons et al., 1998). RA patients seem to have increased risk of lymphoma (Isomäki et
al., 1978; Hakulinen et al., 1985; Bäcklund et al., 2006), leukaemia (Isomäki et al., 1978; Hakulinen
et al., 1985; Cibere et al., 1997), and myeloma (Isomäki et al., 1978; Hakulinen et al., 1985). The
risk of lymphoma is substantially increased in RA patients with very severe disease (Bäcklund et
al., 2006). In the development of lymphoma, the major risk determinant appears to be high
inflammatory activity, rather than RA medication (Bäcklund et al., 2006). Besides LPM, mortality
also seems to be increased due to lung cancer (Thomas et al., 2003). On the other hand, RA patients
may have reduced mortality due to malignancies of the GI tract (Laakso et al., 1986b; Thomas et
al., 2003). The risk for development of colorectal cancer is especially reduced in RA (Cibere et al.,
1997).
Use of ASA and non-ASA non-steroidal anti-inflammatory drugs (NSAIDs) may have
protective effects against development of various malignancies, particularly development of
colorectal cancer (Gwyn and Sinicrope, 2002). In large prospective epidemiological studies on
samples of non-institutionalized US inhabitants, use of ASA has been associated with reduced risk
of lung cancer (Schreinemachers and Everson, 1994), breast cancer (Schreinemachers and Everson,
1994; Johnson et al., 2002), and colon cancer (Schreinemachers and Everson, 1994). Furthermore,
non-ASA NSAIDs, but not ASA, were associated in a large epidemiological study on British
primarycare subjects with slightly reduced risk of lung cancer (Hernandez-Diaz and Garcia
Rodriguez, 2007). Prospective randomized trials have shown the NSAID sulindac and the selective
cyclo-oxygenase-2 (COX-2) inhibitor celecoxib regress adenomas in patients with familial
adenomatous polyposis (Gwyn and Sinicrope, 2002). However, there is some controversy about the
suggestion that ASA and non-ASA NSAIDs protect against malignancies. One large prospective
cohort study on female RA and osteoarthritis patients reported use of either ASA or non-ASA
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NSAIDs to be associated with increased risk of developing non-Hodgkin lymphoma (Cerhan et al.,
2003). The authors reported that the increased risk was independent of a history of RA. With
respect to mortality, ASA has shown beneficial effects. In a large prospective population-based
study on postmenopausal women, use of ASA was associated with decreased overall mortality as
well as decreased mortality due to malignancies and CHD (Bardia et al., 2007).
2.3.2.6 Other causes
Mortality in RA is attributed to disorders of the upper GI tract (Sihvonen et al., 2004a) such as
haemorrhage (Vandenbroucke et al., 1984). Age, glucocorticoid (GC) use, NSAID dose, disability
level, and previous NSAID-induced GI symptoms are independent risk factors for serious GI events
(Singh, 1998). In RA patients, mortality due to chronic obstructive pulmonary disease (Thomas et
al., 2003) and renal failure (Symmons et al., 1998; Thomas et al., 2003) are also increased.
Nephropathy in RA patients presenting with combined haematuria and proteinuria, proteinuria,
microalbuminuria, or histologically confirmed amyloidosis is linked to increased mortality, whereas
mortality is within expected limits in those with isolated haematuria or mesangial
glomerulonephritis (Sihvonen et al., 2004b).
2.3.3 Mortality and rheumatoid arthritis medication
Medication for RA is likely to play a role in mortality. The use of any DMARD (Wållberg-Jonsson
et al., 1997), aurothiomalate (Lehtinen and Isomäki, 1991), or anti-tumour necrosis factor (TNF)
alpha therapy (Jacobsson et al., 2007) has been associated with reduced mortality. Good response to
medication, such as methotrexate (MTX), has been associated with reduced mortality (Krause et al.,
2000).
Inflammation in RA seems to play a significant role as a risk factor for the development of
atherosclerosis (Van Doornum et al., 2002). The risk of cardiovascular death, which constitutes the
majority of deaths in RA, may be reduced by the use of effective medication for RA, such as MTX
(Choi et al., 2002; Krishnan et al., 2004). However, there is some controversy about this issue, as
the use of MTX increases levels of homocysteine (Landewe et al., 2000). RA patients treated with
anti-TNF alpha therapy have a lower risk of developing CVD (Jacobsson et al., 2005). Particularly,
RA patients who respond to anti-TNF alpha therapy experience, unlike non-responders, a reduction
in the incidence of myocardial infarction (Dixon et al., 2007). This is in agreement with the
hypothesis that inflammation contributes to the development of cardiovascular events. Further,
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antimalarials appear, at least in patients with systemic lupus erythematosus, to have beneficial
effects on lipid profiles (Munro et al., 1997).
GCs and NSAIDs may have unfavourable effects on blood pressure, serum glucose, and lipid
profiles, all of which are risk factors for development of CVD (Nashel, 1986; Hermann and
Ruschitzka, 2007; Panoulas et al., 2008). Epidemiological studies have raised concern about the
safety of both selective COX-2 inhibitors and non-selective NSAIDs (Hippisley-Cox and Coupland,
2005; Gislason et al., 2006). In primary care subjects, use of rofecoxib, diclofenac, and ibuprofen
was associated with, after adjustment for several potential confounders, an increased risk of
myocardial infarction (Hippisley-Cox and Coupland, 2005). One meta-analysis suggested that use
of naproxen may have a slight protective effect against cardiovascular events (Juni et al., 2004), but
this issue is controversial (Hippisley-Cox and Coupland, 2005). In patients with previous
myocardial infarction, selective COX-2 inhibitors in all dosages and non-selective NSAIDs in high
dosages seemed to increase mortality (Gislason et al., 2006). However, use of NSAIDs by patients
with recent onset of inflammatory polyarthritis in a primary care-based inception cohort was not
associated with cardiovascular mortality (Goodson et al., 2008b).
In the literature, discrepant reports have emerged about the use of GCs and cardiovascular risk.
In one population-based cohort study of RA patients, particularly RF-positive patients were after
GC exposure at increased risk for cardiovascular events (Davis et al., 2007). Nevertheless,
cardiovascular risk in RF-seropositive RA patients recruited from hospital (inpatients, outpatients,
and consultation patients) was not associated with GC use (Wållberg-Jonsson et al., 1997). One
large case-control study on primary care subjects with at least one prescription of oral GCs showed
that use of GCs was associated strongly with heart failure and weakly with ischaemic heart disease
(Souverein et al., 2004). That study also reported GCs to have a protective effect against stroke and
transient ischaemic attack. The authors suggested that using GCs is a balance between adverse and
potentially protective effects. In patients using MTX, the concentration of homocysteine, a known
cardiovascular risk factor, may be elevated (Whittle and Hughes, 2004). However, this phenomenon
can be offset by using supplemental folates (Whittle and Hughes, 2004).
The use of cyclophosphamide (CYC) is associated with development of cancers, particularly of
bladder cancer (Radis et al., 1995; Beauparlant et al., 1999). The use of azathioprine (AZA) is
associated with development of lymphomas (Silman et al., 1988; Beauparlant et al., 1999). A meta-
analysis covering the period from 1996 to December 2005 reported the use of anti-TNF alpha
therapy, i.e. infliximab and adalimumab, to be associated with an increased risk of severe infections
and also with dose-dependent increased risk of malignancies such as non-melanoma skin cancers
and lymphoma (Bongartz et al., 2006). That analysis, however, has been criticized because it
excluded studies on etanercept (Callegari et al., 2006). Furthermore, the analysis was conducted just
before publishing a large study on adalimumab (Breedveld et al., 2006). Had this study on
adalimumab been included in the meta-analysis, the odds ratio for malignancy would have been
lower (Costenbader et al., 2006). One study focusing on biological treatment – including
infliximab, etanercept, adalimumab, and anakinra – and malignancies using a large US database
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reported the risk for various kinds of skin cancers to be increased, but this was not true for solid
tumours or LPMs (Wolfe and Michaud, 2007).
Use of DMARDs, including MTX, does not increase the risk of infection, whereas use of GCs
does (Coyne et al., 2007; Lacaille et  al., 2008). GC use is especially linked to increased risk of
lower respiratory tract infections (Sihvonen et al., 2006; Coyne et al., 2007), which have a
relatively high mortality (Coyne et al., 2007). With the exception of one study (Mitchell et al.,
1986), GC use has been found to predict mortality (Leigh and Fries, 1991; Wolfe et al., 1994).
Wolfe et al (1994) concluded that GC use was a marker of RA severity.
In one population-based RA mortality study, medication contributed to the death of 47 RA
patients (3%) who died in 1989 (Myllykangas-Luosujärvi et al., 1995b). In that study, the vast
majority of deaths were estimated to be attributed to the use of non-selective NSAIDs or GCs. Use
of non-selective NSAIDs increases the risk of serious GI events approximately 3-fold (Lichtenstein
et al., 1995). That risk may be higher in the elderly, in those with prior ulcer disease, in those taking
concomitant GCs, and in those taking high-dose or multiple NSAIDs (Lichtenstein et al., 1995).
Furthermore, NSAID-induced GI injury may occur with no prior symptoms (Singh, 1998).
However, the selective COX-2 inhibitors, introduced at the turn of the century, have proven less
harmful to GI mucosa (Simon et al., 1999).
The earlier RA medication starts, the better the outcome. RA patients referred early in the
disease course do better than those referred late (Symmons et al., 1998). There seems to be a
window of opportunity for starting RA medication (Quinn and Emery, 2003; Cush, 2007). An early
start of RA medication, preferably during the first three months of symptom onset, seems to be
crucial in achieving optimal control of disease progression and improved prognosis (Nell et al.,
2004).
2.4 Methodological aspects in rheumatoid arthritis mortality studies
2.4.1 General issues
Several important aspects should be considered when interpreting findings from various RA
mortality studies. The number of patients may be highly variable, and conclusions based on only a
few RA patients are generally unreliable. Study settings vary from the general population to tertiary
care hospitals treating patients with the most severe RA. Furthermore, patients are recruited from
various geographical sites. Findings derived from patients treated at a tertiary care hospital may
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only be generalized to similar patients. Some RA mortality studies are prospective cohort studies,
while others are retrospective, cross-sectional, or autopsy-based studies. Follow-up studies have had
highly variable follow-up periods. Furthermore, follow-up studies do not follow all of their RA
patients until death, although CoDs change with advanced age as well as along the course of RA
(Symmons et al., 1998).
2.4.2 Study populations
RA mortality studies use different inclusion criteria for RA. Several studies have used classification
criteria for RA. However, before 1958, no classification criteria existed for RA. In 1958, the
American Rheumatism Association (ARA) criteria were created (Ropes, 1959) (Table 6). The 1958
ARA criteria classified the disease as classical, definite, probable, and possible RA based on criteria
comprising clinical, serological, radiological, and histological features. The revised ARA criteria
from 1987 were based on those earlier criteria, but accommodated the characteristic pattern of joint
involvement more precisely (Arnett et al., 1988) (Table 7). However, no RA classification criteria
are absolutely specific and sensitive. One review article reported that the 1958 ARA criteria showed
a sensitivity varying from 71% to 100% and a specificity varying from 77% to 98%; and the 1987
ARA criteria showed a sensitivity from 66% to 95% and a specificity from 74% to 98%
(MacGregor, 1995). That review also stated that the 1987 ARA criteria may have enhanced
specificity, compared with the 1958 criteria, but sensitivity may be reduced (MacGregor, 1995).
Another review article estimated that the 1958 ARA criteria possess a weakness because much
emphasis is placed on soft-tissue swelling, which has low specificity and poor interobserver
reproducibility (Aho et al., 1998). That review article considered the presence of clinical arthritis or
deformities of previous arthritis, associated with RF positivity or radiological changes typical of
RA, to be a more reliable measure of clinically significant chronic peripheral arthritis, i.e. RA, than
RA defined by the 1958 ARA criteria (Aho et al., 1998) (Table 8). A study on prevalence of RA in
the United Kingdom suggested a similar approach (Symmons et al., 2002). In that study, besides
active arthritis presenting with joint swelling, the authors also analyzed joint deformities as a
sequela to previous arthritis. Therefore, those RA patients who were in remission at the time of the
study could also be detected. Furthermore, the 1987 ARA criteria have been unable, among patients
with recent onset of inflammatory polyarthritis, to distinguish between patients who later develop
persistent, disabling, and erosive polyarthritis and those who do not (Harrison et al., 1998).
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Table 6.   The 1958 American Rheumatism Association (ARA) criteria for rheumatoid arthritis
1.  Morning stiffness.
2. Pain on motion or tenderness in at least one joint (observed by a physician).
3. Swelling (soft tissue thickening or fluid, not bony overgrowth alone) in at least one joint (observed by a physician).
4. Swelling (observed by a physician) of at least one other joint (any interval free of joint symptoms between the two joint involvements may be
no more than 3 months).
5. Symmetrical joint swelling (observed by a physician) with simultaneous involvement of the same joint on both sides of the body (bilateral
involvement of the mid-phalangeal, MCP, or MTP joints is acceptable without absolute symmetry). Terminal IP joint involvement will not
satisfy the criterion.
6. Subcutaneous nodules (observed by a physician) over bony prominences, on extensor surfaces, or in juxta-articular regions.
7. X-ray changes typical of RA (which must include at least bony decalcification localized to or greatest around the involved joints and not just
degenerative changes). Degenerative changes do not exclude patients from any group classified as RA.
8. Positive agglutination test demonstration of RF by any method, which in two laboratories has been positive in not over 5% of normal controls,
or positive streptococcal agglutination test.
9. Poor mucin precipitate from synovial fluid (with shreds and cloudy solution).
10. Characteristic histological changes in synovial membrane with three or more of the following: marked villous hypertrophy; proliferation of
superficial synovial cells often with palisading; marked infiltration of chronic inflammatory cells (lymphocytes or plasma cells predominating)
with tendency to form “lymphoid nodules”; deposition of compact fibrin, either on surface or interstitially; foci of cell necrosis.
11. Characteristic histological changes in nodules showing granulomatous foci with central zones of cell necrosis, surrounded by proliferated fixed
cells, and peripheral fibrosis and chronic inflammatory cell infiltration, predominantly perivascular.
Classical RA requires 7/11 criteria with 1-5 present continuously for 6 weeks;
Definite RA requires 5/11 criteria with 1-5 present continuously for 6 weeks;
Probable RA requires 3/11 criteria with at least one of 1-5 present continuously for 6 weeks;
Possible RA requires two of the following criteria and a total duration of joint symptoms of at least three weeks: (1) Morning stiffness, (2) tenderness
or pain on motion with a history of recurrence or persistence for three weeks, (3) history or observation of joint swelling, (4) subcutaneous nodules,
(5) elevated sedimentation rate or C-reactive protein, or (6) iritis. MCP=metacarpophalangeal; MTP=metatarsophalangeal; IP=interphalangeal;
RA=rheumatoid arthritis; RF=rheumatoid factor.
Exclusions: Typical rash of systemic lupus erythematosus, high concentration of lupus erythematosus cells, histological evidence of periarteritis
nodosa, weakness of the neck, trunk, and pharyngeal muscles or persistent muscle swelling of dermatomyositis, scleroderma, rheumatic fever, gouty
arthritis, tophi, acute infectious arthritis, joint tuberculosis, Reiter's syndrome, shoulder-hand syndrome, hypertrophic pulmonary osteoarthropathy,
neuroarthropathy, homogentisic acid in the urine, histological evidence of sarcoid or a positive Kveim test, multiple myeloma, erythema nodosum,
leukaemia or lymphoma, or agammaglobulinaemia. Adapted from Ropes et al (1959). Modified and re-printed with kind permission of BMJ
Publishing Group Ltd.
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Table 7.   The revised 1987 ARA criteria for rheumatoid arthritis
1. Morning stiffness Morning stiffness in and around the joints, lasting at least one hour before maximal
improvement for at least 6 weeks.
2. Arthritis in three or more joint areasa Soft tissue swelling or fluid (not bony overgrowth) observed by a physician, present
simultaneously for at least 6 weeks.
3. Arthritis of hand joints Swelling of wrist MCP or PIP for at least 6 weeks.
4. Symmetrical arthritis Simultaneous involvement of the same joint areas (defined in 2) on both sides of the body
(bilateral involvement of PIPs, MCPs, or MTPs is acceptable without absolute symmetry) for
at least 6 weeks.
5. Rheumatoid nodules Subcutaneous nodules over bony prominences, or extensor
surfaces, or in juxta-articular regions, observed by a physician.
6. Rheumatoid factor Detected by a method positive in less than 5% of normal controls.
7. Radiographic changes Typical for RA on posteroanterior hand and wrist radiographs, which must include erosions
or unequivocal bony decalcification localized to or most marked adjacent to the involved
joints (OA changes alone do not qualify).
At least four criteria must be fulfilled for classification as RA. MCP=metacarpophalangeal; MTP=metatarsophalangeal; OA=osteoarthritis;
PIP=proximal interphalangeal; RA=rheumatoid arthritis. aPossible areas: right or left PIP, MCP, wrist, elbow, knee, ankle, MTP. Adapted from Arnett
et al (1988). Modified and re-printed with kind permission of Wiley Interscience.
Table 8.  Classification criteria for chronic rheumatoid arthritis suggested by Aho et al
1. Clinical arthritis (or deformities of past arthritis)
2. Positive rheumatoid factor serology
3. Radiographic changes typical of rheumatoid arthritis
Diagnosis of rheumatoid arthritis requires presence of clinical arthritis associated with positive serology or characteristic radiographic changes or
both. Adapted from Aho et al (1998).
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2.4.3 Presentation of results
Early studies on RA mortality have used proportional mortality statistics, which express deaths
from a particular cause as a percentage of the total number of deaths. This may cause
misinterpretations. Monson and Hall (1976) reported deaths from malignancies in patients with RA
or osteoarthritis to be less than expected using proportional mortality analysis, but more than
expected using absolute figures. When using absolute figures, mortality can be expressed over a
follow-up period as relative risk (RR), which compares the number of deaths in a RA population
with the number of deaths in a non-RA population, or as standardized mortality ratio (SMR), which
compares the number of deaths in a RA population to the number of deaths in the general
population. Some issues to consider emerge when interpreting SMR, which is used in several
studies. SMR is influenced by the background population from which the RA population is drawn
and by the length of follow-up. The longer patients are followed up, the more likely the SMR is to
approach 1. This is explained by the fact that all patients eventually die. If the follow-up is extended
sufficiently long, e.g. 100 years, the SMR will be 1. Mortality can also be expressed as a life-table
survival curve showing cumulative probability of survival of a cohort. Furthermore, mortality can
be expressed as a shortening of lifespan (Symmons, 1988; Myllykangas-Luosujärvi et al., 1995;
Naz and Symmons, 2007).
Official death certificates have three classes of CoDs, i.e. immediate, underlying, and
contributory, all of which have an effect on CoD sequence.  This sequencing of CoDs is based on
guidelines established by the World Health Organization (WHO). Underlying CoD is the basic
disease that initiated the cascade of morbid events leading to death. Immediate CoD is the final
disease or condition directly causing death. Contributory CoDs are coexisting conditions that
contributed to death, but did not result in the underlying CoD. Underlying and immediate CoDs are
always required in the CoD sequence.
CoD analyses are frequently based on solely the underlying CoD. However, an analysis based
solely on underlying cause may underestimate the contribution of a disease (Redelings et al., 2006),
such as heart failure (Murdoch et al., 1998) and chronic obstructive pulmonary disease (Fuhrman et
al., 2006), to mortality. Because chronic diseases, such as RA, often cause death in association with
other co-morbidities, it is preferable to analyse the contribution of chronic disorders to mortality by
using multiple CoDs (Ziade et al., 2008).
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2.4.4 Accuracy of cause-of-death data
CoD determination is frequently based on clinical judgement without verification by autopsy,
although autopsy is regarded as the gold standard (Goldman et al., 1983; Welsh and Kaplan, 1998).
A meta-analysis covering the years 1980 to 2004 reported that without autopsy discrepancies
between clinical diagnoses of CoD and those made at autopsy had been detected in 46% of cases
(Roulson et al., 2005). Despite advances in medical technology, clinically determined CoD may be
inaccurate (Kirch and Schafii, 1996). Especially in CoD determination for critically ill patients,
autopsy is important (Roosen et al., 2000; Twigg et al., 2001; Perkins et al., 2003; Combes et al.,
2004). In such patients, discrepant major diagnoses before autopsy have ranged from 20% to 39%
(Roosen et al., 2000; Twigg et al., 2001; Perkins et al., 2003; Combes et al., 2004).
The main diagnoses leading to discrepancies in general patient populations have been
pulmonary embolism, CVDs, including myocardial infarction, and infections (Roulson et al., 2005).
Furthermore, reactive AA amyloidosis, which can be a life-threatening manifestation of RA, may
go undetected during the lifetime (Teilum and Lindahl, 1954; Wright and Calkins, 1981; Browning
et al., 1985).
Classification of CoDs according to the International Classification of Diseases (ICD) system
may also cause bias in interpretation of RA mortality studies. Infections are classified, except for
septicaemia and epidemic infections, under the organ system that they affect. Reactive amyloidosis
associated with RA may appear, according to its typical clinical manifestation, as renal failure.
Furthermore, information about reactive amyloidosis in an analysis of underlying CoDs may remain
undiscovered because, according to guidelines of the WHO, it is not to be coded as an underlying
CoD. According to the WHO, reactive amyloidosis may appear as an immediate, contributory, or
intervening antecedent CoD.
National mortality statistics are likely to be deficient. Of death certificates, 10% (Ermenc, 1999)
to as high as 96% (Pritt et al., 2005) are completed inappropriately. Errors may also occur at the
coding stage.
31
3. Aims of the study
The aim of this study was to evaluate determinants of RA mortality by clarifying CoDs and their
changes over time, with special emphasis on CoDs in a population of autopsied RA patients, with
non-RA patients serving as reference cases. This study also evaluated the contribution of autopsy to
CoD determination, the contribution of RA medication to CoDs, and the detection rate of amyloid
deposits.
Specific aims were as follows:
1. To analyse in a large RA population CoDs and changes in CoDs over a 21-year period (Study I).
2. To evaluate whether CoDs were similar in RA patients not autopsied and those who had
undergone autopsy (Study I).
3. To examine in consecutively autopsied RA patients and their reference cases CoDs and changes
in CoDs over 40 years (Study II), especially CoDs due to infections (Study III) or reactive
amyloidosis (Study IV).
4. To investigate the contribution of autopsy to CoD diagnoses (Studies II-IV).
5. To clarify the detection rate of reactive amyloidosis in autopsied RA patients at three levels: 1)
during the course of RA, 2) at routine autopsy, and 3) at systematic re-examination of autopsy tissue
samples of the same patients (Study V).
6. To evaluate the contribution of RA medication to CoDs (Studies II-IV).
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4. Patients and methods
4.1 Setting
Patients had been treated at Kivelä Municipal Hospital, Helsinki, Finland. During the study period,
the hospital was an acute-care facility responsible for specialized health care of internal diseases
and for primary to tertiary treatment of RA in the Helsinki area. The RA patients were treated by
rheumatologists, and it was standard practice to commence treatment with a DMARD in the
hospital ward.
4.2 Patients
4.2.1 Study population A
All RA patients treated and deceased between 1971 and 1991 at Kivelä Hospital were identified
from the Hospital Discharge Register maintained by the National Research and Development
Centre for Welfare and Health (STAKES). Of the 3186 RA patients treated as inpatients because of
RA, 960 died (712 females, 248 males). Statistics Finland provided the information on their death
certificates. Because the identification code came into regular use at the beginning of the 1970s, the
study included RA patients deceased from 1971 onwards. Over the 21 year period, the autopsy rate
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Figure 1. Autopsy rate of RA patients from 1971 to 1991, Study population A (unpublished data).
RA patients died frequently at secondary or tertiary care hospitals (Table 9). Of the 960 patients,
223 (23%) died at Kivelä Hospital. Of these patients, 65% were autopsied at Kivelä Hospital
(unpublished data).
Table 9. Rate of autopsies according to the location of death






Secondary or tertiary care hospitalb 389 (65) 347 (58) 42 (7)
Primary care hospital 42 (20) 36 (17) 6 (3)
Home 58 (70) 13 (16) 45 (54)
Primary care centre 1 (100) 1 (100) 0 (0)
Old age home 6 (15) 6 (15) 0 (0)
Other 17 (74) 2 (9) 15 (65)
Total 513 (53) 405 (42) 108 (11)
aproportion of autopsies of all deaths at that particular location; bmunicipal or central hospital  (unpublished data).
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4.2.2 Study population B
All patients with a diagnosis of RA were identified from the autopsy register at Kivelä Hospital.
This register, covering the years from 1946 to 1991, included referrals for autopsy with clinicians'
diagnoses of CoD, autopsy reports, and CoD data. For each of the consecutively autopsied 591 RA
patients, the next autopsied patient without any rheumatic disorder (non-RA) of the same sex, the
same age at death (within a 2-year margin), and the same year of autopsy was chosen as a reference
case. Patients with RA, spondylarthropathy, systemic lupus erythematosus, or any other rheumatic
disorder, but not those with degenerative joint disease, were excluded from the non-RA population.
Because 95% of the medical records before 1973 had been destroyed (archiving legislation, 1989)
and because no international diagnostic criteria existed for RA before 1958, modified criteria for
RA were set according to Aho et al (1998) (Table 8) in a review article on epidemiology of RA in
Finland. The Aho group criteria were modified as follows: (i) for RA patients with unavailable
medical records, diagnosis was based on the following findings at autopsy: erosions or macroscopic
synovitis of a dissected joint or deformities typical of chronic RA at inspection or any combination
of these, and (ii) if medical records were available, patients with clinical polyarthritis and joint
erosions or rheumatic involvement of the cervical spine on radiographs or positive RF or both were
included. Those RA patients who fulfilled these modified criteria (and their reference cases) were
included in the study. Because very few RA patients fulfilled the modified criteria for RA earlier,
the starting point for the study was 1952. Between 1952 and 1991, the mean autopsy rate was 67%.



















       Figure 2. Autopsy rate from 1952 to 1991, Study population B (unpublished data).
35
Patients with an autopsy referral from a trauma hospital (Töölö Hospital) or a psychiatric hospital
(the Hesperia Hospital) were excluded. Data for infectious CoDs were available for 369 RA patients
and 371 non-RA patients, but one non-RA patient was subsequently excluded from analyses
because of insufficient data. Thus, the patient pool in the other analyses comprised 369 RA patients
(280 females, 89 males), with 370 non-RA patients (282 females, 88 males) serving as reference
cases. Study population B contained 145 RA patients who were also included in Study population
A. See Figure 3 for selection of patients and Table 10 for inclusion criteria fulfilled by the RA
patients in Study population B.
 Figure 3. Patient selection. Inclusion of patients: clinical or autopsy criteria or both fulfilled.
Patients from a trauma or psychiatric hospital excluded. Analysis of infectious deaths included 371
non-RA cases, see text above for explanation.
591 RA patients 591 non-RA patients
369 RA patients autopsied in
1952-91
370 non-RA patients matched
with RA autopsied in 1952-91
Same sex, age at death, and year of
autopsy (1946-91)
Inclusion criteria +







Table 10. Inclusion criteria fulfilled by rheumatoid arthritis patients
Clinical criteriaa: Number of patients
(Positive finding/all studied)
Polyarthritis
     - with positive rheumatoid factor, but no radiographic changes 12/178
     - with rheumatic changes on radiographsb, but negative rheumatoid factor 17/178
     - with positive rheumatoid factor and rheumatic changes on radiographs 149/178
Autopsy criteriac:
Synovitis or erosions or both in a dissected joint 113/140
Findings of chronic RA at inspection 262/275
Both findings of dissected joint and chronic RA at inspection 74/353
abased on medical records systematically available between 1973 and 1991; berosions of joints or rheumatic involvement of the cervical spine; cbased
on autopsy reports between 1952 and 1991.
The time period 1952 to 1972 included 183 RA and 185 non-RA patients. From 1973 to 1991, the
corresponding figures were 186 and 185. Before 1973, only very few medical records were
available. Therefore, subsequent analyses of clinical data are based on medical records of RA
patients autopsied from 1973 onwards. Of the 186 RA patients autopsied between 1973 and 1991,
medical records were available for 175. Clinical characteristics of these patients were evaluated
(Table 11). However, descriptions of clinical features of RA were unavailable for some patients
with limited medical records were very limited. Extra-articular features, for example, were
investigated for 162 RA patients (Table 12, unpublished data). In RA patients, information was also
recorded regarding the presence of co-morbid conditions, life-time biopsy findings for detecting
amyloid, and functional status estimated according to Steinbrocker (1949).
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Table 11. Clinical data recorded from medical records for 175 rheumatoid arthritis patients autopsied
from 1973 to 1991
Rheumatoid factor Regarded as positive:
i) + (if qualitative)
ii) Latex > 32 (a reciprocal of titre)
iii) Waaler-Rose > 64 (a reciprocal of titre)
Duration of RA Time period from diagnosis of RA to death (years)
Extra-articular features Presence of rheumatic nodules, serositides, rheumatic lung involvement, rheumatic eye involvement, vasculitis,
and neuropathy estimated to be associated with RA, Felty’s syndrome, or any combination of these
Radiographic changes Presence of erosions in joints or rheumatic involvement of the cervical spine
Medication i) Disease-modifying anti-rheumatic drugs
ii) Glucocorticoids
iii) Cumulative duration of the use of these drugs
Laboratory tests Mean of the values:
i) Erythrocyte sedimentation rate
ii) Blood haemoglobin
iii) Persistent proteinuriaa defined as:
 - proteinuria  > 1+/3+, if semi-quantitative (urine dipstick)
 - urinary protein secretion > 0.3 g/24 h.
Orthopaedic operations Synovectomy, prosthetic joint replacement, resection of metatarsophalangeal joints,
arthrodesis,  atlanto-occipital fusion operation, or any combination of these
Abnormalities in ECG Ischaemia, conduction defects, arrhythmias, low voltage, or any combination of these
Functional status From I to IV according to Steinbrocker  et al (1949)
ECG=electrocardiogram; apersistent proteinuria was recorded when proteinuria was detected in medical records at least twice.
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Table 12. Clinical features of RA patients autopsied from 1973 to 1991
Clinical feature RA patients
Rheumatoid factor positivitya; n (%) 151 (92)
Radiographic changes typical of RAb; n (%) 151 (94)
Extra-articular featuresc; n (%)
  - Rheumatic nodules
  - Pericarditis
  - Pleuritis
  - Vasculitis
  - Neuropathy
  - Rheumatic involvement of lungs
  - Secondary sicca syndrome










Duration of RA (years); mean+SD 17+11
Steinbrocker III-IV; n (%) 137 (82)
Orthopaedic operations; n (%) 56 (35)
Radiotherapy; n (%) 16 (10)
Erythrocyte sedimentation rate (mm/h); mean+SD 57+24
Blood haemoglobin (g/l); mean+SD 116+16
adata available for 164 patients; bdata available for 160 patients; cdata available for 162 RA patients (unpublished data).
Between 1973 and 1991, at least one DMARD, as a monotherapy or in combination, had been used
by 138 patients (82%). Of the RA patients autopsied from 1973 to 1991, 86 (53%) had been on
GCs, 142 (95%) on ASA, and 160 (99%) on some other NSAID. Between 1973 and 1991, the most
frequently used DMARDs were aurothiomalate with or without antimalarials (106 patients). A few
patients had been on cyclophosphamide (seven patients) or azathioprine (three patients). The most
frequently used first DMARD was aurothiomalate or antimalarials, as a monotherapy or in
combination (Figure 4). The median duration of DMARD usage was 3 years (Figure 5), and the
median duration of RA for patients using DMARD was 16 years (IQR; 10-26). Thus, duration of
treatment with DMARDs covered approximately one-fifth of the RA duration. The median duration
of GC usage was 2 years (Figure 5), and the median duration of RA for patients using GCs was 17
years (IQR; 10-28). Thus, duration of treatment with GCs covered approximately one-eight of the
RA duration. Between 1973 and 1991, the proportion of patients receiving DMARDs or GCs or






















1973-76 1977-81 1982-86 1987-91
Figure 4.  First medication for rheumatoid arthritis from 1973 to 1991 (unpublished data).
Figure 5. Duration of DMARDs in 129 RA patients and duration of GCs in 81 RA patients autopsied
from 1973 to 1991. The box represents median (horizontal line in the box) and interquartile range
(IQR). Whiskers show 5th and 95th percentiles. Circles represent outliers (unpublished figure).
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All patients underwent complete autopsies. These autopsies included macroscopic assessment of the
brain and internal organs, along with histological examination of routine samples (e.g. heart, lungs,
liver, and kidneys) and organs with suspected abnormality. Furthermore, autopsies included
inspection of the musculoskeletal system and histological examination of joints, when arthritis was
suspected.
4.3 Methods
CoDs and their changes over a 21-year period were examined in a large population of RA patients
(Study population A). A population of autopsied RA patients with non-RA patients serving as
reference cases was examined next. In autopsied patients, the study evaluates CoDs and their
changes over 40 years (Study population B), the accuracy of CoD determination, the contribution of
DMARDs to the CoDs, and the detection rate of reactive amyloidosis.
The CoD data were obtained from death certificates (Study populations A and B). Unless
otherwise stated, CoD data included multiple CoDs, i.e. immediate, underlying, contributory, and
intervening antecedent CoDs. The CoD data for autopsied patients were based on autopsy.
Proportional mortality statistics, which express deaths from a particular cause as a percentage of
the total number of deaths, may cause bias. To overcome this, this study evaluated multiple CoDs,
the immediate cause, the underlying cause, and, with respect to CVDs, also of atherosclerotic
findings in coronary arteries at autopsy (Study population B).
Data about CoDs before autopsy estimated by the clinician were derived from referrals for
autopsy (Study population B). The accuracy of CoD determination was examined by comparing the
diagnosis set by the clinician before autopsy with that determined at autopsy by the pathologist
(Study population B).
In Study population B, clinical data during the course of RA were obtained from medical
records systematically available from 1973 onwards. This data included the detection rate of
amyloidosis during the course of RA, clinical features of RA, and medication for RA.
In Study population B, macroscopic and histological data were obtained from autopsy reports.
This data included findings of reactive amyloidosis at any site and atherosclerotic findings in
coronary arteries.
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The detection rate of amyloidosis was examined at three levels 1) during the course of RA (data
from medical records), 2) at the time of routine autopsies of RA and non-RA cases (data from
autopsy reports), and 3) at re-examination of tissue samples taken from the same RA and non-RA
cases. Furthermore, typing of amyloid was conducted in kidney samples.
4.3.1 Causes of death
Causes of death were recorded as follows:
Cardiovascular diseases: i) Cardiac: coronary heart disease; pericarditis, myocarditis, or
endocarditis, or any combination of these; hypertensive heart
disease, valvular disease, heart failure, cor pulmonale, and
cardiomyopathy.
ii) Cerebrovascular: cerebral infarction, haemorrhage, and
cerebrovascular atherosclerosis.
iii) Vascular: pulmonary embolism, aortic aneurysm, and
vasculitis.
 Respiratory diseases:  chronic obstructive pulmonary disease, pulmonary fibrosis, or
emphysema, or any combination of these, pulmonary infarction,
bronchial asthma, and bronchiectasis.
 Renal diseases: nephropathy of unknown aetiology, glomerulonephritis, and
interstitial nephritis.
Gastrointestinal disorders: peptic ulcer, diverticular disease of the colon, inflammatory
bowel diseases, mesenteric arterial infarction, paralytic ileus,
appendicitis, cholecystitis, pancreatitis, hepatitis, and cirrhosis
of the liver.
Endocrinological diseases: diabetes mellitus, Addison’s disease, hyper- or hypothyreosis,
and hyper- or hypoparathyreosis.
Infections: pulmonary infections, tuberculosis, sepsis, peritonitis,
pyelonephritis, infections of the central nervous system,
sexually transmitted diseases, and gastroenteritis.
Rheumatoid arthritis: RA with or without secondary complications, such as reactive
amyloidosis, serositides, rheumatic lung involvement, or
rheumatic eye involvement, Felty’s syndrome, vasculitis, and
neuropathy.
Malignancies: malignancies of various internal organs, breast, skin, bone,
and the haematopoietic system
Haematological diseases:  aplastic anaemia, leukocytopenia, and thrombocytopenia
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4.3.2 Contribution of autopsy to cause-of-death diagnosis
If a CoD was not mentioned on referral by the clinician, but determined as such at autopsy by the
pathologist, the CoD was considered to be unrecognized by the clinician. Besides false-negative
CoDs, there may also be false-positive CoDs. Therefore, agreement between clinical diagnoses of
CoDs and those determined at autopsy was estimated by the kappa reliability measure, in which
agreement between diagnoses was low at <0.40, medium at 0.40–0.75, and high at >0.75.
4.3.3 Autopsy tissue samples
In Study population B, autopsy tissue samples were re-examined in 328 RA patients (89%) and in
336 non-RA patients (91%) to detect amyloid deposits. One pathologist (R.S.) analysed these
samples, which were stained with Congo red, under polarized light for birefringent amyloid without
knowledge of either clinical or autopsy data. Similarly, another pathologist (T.T.) conducted typing
of amyloid by immunohistochemical methods (antiserum against amyloid A) in kidney samples. A
patient with amyloid deposits in any tissue was defined as having reactive amyloidosis.
4.3.4 Statistical analysis
Statistical analysis was performed with the NCSS software (NCSS 6.0; Statistical software,
Kaysville, UT, USA) and with SPSS software (SPSS, Inc., Chicago, IL, USA). Comparisons
between groups for binary variables were performed with 2 or Fisher's exact test as appropriate.
Continuous variables were compared by using Student's t-test. Statistical significance for
hypotheses of linearity was evaluated by analysis of variance (ANOVA), Cochran-Armitage test, or
linear-by-linear association test. Logistic regression analysis was applied to obtain age- and sex-
adjusted probabilities. Agreement between clinical and autopsy-based diagnoses of CoDs was
determined by the kappa reliability measure. No adjustment was made for multiple testing, but this
information can be obtained by multiplying the p-value by the number of comparisons made. A p-
value of less than 0.05 was considered significant.
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5. Ethical considerations
The Ethics Committee of Helsinki University Central Hospital provided a favourable opinion on the
study protocol. Ministry of Social Affairs and Health approved the study protocol. Statistics Finland
gave permission to use of CoD data.
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6. Results and discussion
Study population A comprised 960 RA patients, 53% of whom were autopsied. Study population B
comprised 369 autopsied RA patients, with 371 autopsied non-RA patients serving as reference
cases. In Study population B, data for infectious CoDs were available for 369 RA patients and 371
non-RA patients, but one non-RA patient was subsequently excluded from analyses because of
insufficient data.
6.1 Study population A
In patients deceased between 1971 and 1991, the mean age at death + standard deviation (SD) was
71 + 10 years. During the 21-year period, the mean age at death increased in females from 64 to 74
years (p-value for linear trend<0.001) and in males from 66 to 70 years (non-significant).
6.1.1 Causes of death
In Study population A, CVDs, infections, and RA itself were the most frequent CoDs (Table 13), in
accordance with several RA mortality studies reporting increased death rate due to CVDs
(Allebeck, 1982; Prior et al., 1984; Wållberg-Jonsson et al., 1997; Symmons et al., 1998; Björnådal
et al., 2002; Sihvonen et al., 2004a; Goodson et al., 2005), infections (Allebeck, 1982; Prior et al.,
1984; Vandenbroucke et al., 1984; Wolfe et al., 1994; Symmons et al., 1998; Sokka et al., 1999;
Björnådal et al., 2002; Sihvonen et al., 2004a), and RA (Allebeck, 1982; Vandenbroucke et al.,
1984; Wolfe et al., 1994; Björnådal et al., 2002).
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Table 13. Causes of death in rheumatoid arthritis patients in Study population A
Multiple cause of death
n (%)
Underlying cause of death
n (%)
Cardiovasculara
   Coronary heart disease
   Cerebrovascularb









Rheumatoid arthritis 430 (45) 172 (18)
Infections
   Respiratoryb
   Urinary tractb
   Sepsisb



































Respiratory diseases 52 (5) 27 (3)
Haematological diseases 9 (1) 5 (1)
Total number of patients 960
aincluding cardiac, cerebrovascular, and vascular causes of death; bunpublished data; cat any site; dpeptic ulcer with complication, perforation of
intestine, or mesenteric infarction, or any combination of these.
Analysis of only underlying CoD, instead of multiple CoDs, seems to underestimate contribution of
various diseases to mortality (see Table 13). However, several RA mortality studies have analysed
only underlying CoD. To enable comparison of the findings in this study with those of others,
multiple CoDs as well as underlying CoDs were analyzed.
Of the 960 RA patients in Study population A, CVD was an underlying CoD in 443 (46%),
consistent with the results of others (Allebeck et al., 1981; Wållberg-Jonsson et al., 1997; Kvalvik
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et al., 2000; Sihvonen et al., 2004a). Some studies have, however, found lower prevalences
(Martinez et al., 2001; Young et al., 2007). One Japanese autopsy-based study reported a very low
figure (17%) for CVD deaths (Suzuki et al., 1994). The study did not, however, specify, whether
these were underlying causes. In Study population A, CHD constituted the majority of
cardiovascular CoDs, in parallel with other reports (Wållberg-Jonsson et al., 1997; Kvalvik et al.,
2000; Young et al., 2007). Of the RA patients in Study population A, CHD appeared as an
underlying CoD in 29%, resembling the findings of other authors (Wållberg-Jonsson et al., 1997;
Kvalvik et al., 2000; Young et al., 2007) (Table 14).
In a multiple CoD analysis, death was caused by infection in 28% of RA patients. Of these
patients, infection was an underlying CoD in only 8%, a figure close to that reported for Norwegian
RA patients for 1977-92 (Kvalvik et al., 2000). One Spanish follow-up study covering the period
from 1989 to 1998 (Martinez et al., 2001) reported a higher proportion of infections than that
observed in Study population A (Table 14). Higher proportions of infections have also been found
in autopsy-based studies covering the period 1959-74 (24%) (Mutru et al., 1976) and 1960-90
(24%) (Suzuki et al., 1994). These two studies did not report whether these were underlying CoDs.
One contributing factor to the high proportion of infections may be that these three studies did not
use the ICD coding system in which infections are recorded under the organ system that they affect
(Mutru et al., 1976; Suzuki et al., 1994; Martinez et al., 2001). However, the explanation for the
rather low proportion of infections in Study population A, where ICD coding was also not used,
remains unclear. The majority of infections in RA patients here were infections of the respiratory
tract, similar to other reports (Prior et al., 1984; Vandenbroucke et al., 1984; Mutru et al., 1985;
Symmons et al., 1998; Sihvonen et al., 2004a).
RA was the CoD in 45% of patients in a multiple CoD analysis and in 18% of patients in an
analysis of underlying CoD, the latter figure being close to that of hospital-based follow-up studies
using underlying CoD (Allebeck, 1982; Symmons et al., 1998; Kvalvik et al., 2000). Compared
with the current finding of 18% of RA patients having RA as an underlying CoD, one population-
based study of Swedish RA patients reported a 3-fold lower figure (Allebeck et al., 1981) (Table
14). The authors noted that RA is often underreported on death certificates.
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Allebeck, 1981 84 49 NA 2 5a 6 1 0 24 NA
Allebeck, 1982 473 37 NA 1 20a 8 5 4 12 NA
Wållberg-Jonsson, 1997 265 53 30 2 9a 6 9 2 14 3
Symmons, 1998 266 39 NA 3 15a 5 15 4 17 NA
Kvalvik, 2000 68 43 22 9 17 NA NA NA 24 NA
Martinez, 2001b 23 21 NA 21 NA NA NA NA 8 NA
Sihvonen, 2004a 384 43 NA 2 8a 5 8 4 18 NA
Young, 2007 459 31 24 5c NA 3 22 2d 24 4
CVD=cardiovascular disease; CHD=coronary heart disease; GI=gastrointestinal; LPMs=lymphoproliferative malignancies; Mal=malignancy;
NA=not available; RA=rheumatoid arthritis; Resp=respiratory; Urogen=urogenital; amusculoskeletal disorders; bthe ICD coding system not used in
classification of causes of death; csepticaemia; drenal failure.
Death due to reactive amyloidosis occurred in 9% of RA patients, close to the findings of a Finnish
hospital-based study (Laakso et al., 1986a). Of the 89 patients with amyloidosis in the present
study, 44% had renal failure as a CoD. Other RA-associated complications than amyloidosis were
very uncommon. These complications included peri- or myocarditis or both (seven patients), acute
medullar compression of the cervical spine or Felty’s syndrome (three patients both), rheumatic
lung involvement or renal failure (two patients both), vasculitis, pleuritis, pulmonary fibrosis and
pneumonitis, some unspecified extra-articular feature, and tetraparesis as a consequence of medullar
compression at the region CIV-V after atlanto-occipital fusion operation (one patient each).
Several hospital-based follow-up studies have reported higher mortality due to reactive
amyloidosis in Finland (9-24%) (Mutru et al., 1976; Laakso et al., 1986a; Lehtinen and Isomäki,
1991) than in other European countries (2-7%) (Prior et al., 1984; Reilly et al., 1990; Kvalvik et al.,
2000), except for Spain (17%) (Martinez et al., 2001) (Table 5). Deaths caused by reactive
amyloidosis, thus, seem to occur more commonly in Finland than in other countries. Genetic
susceptibility for amyloidosis has been suggested to contribute to this, even though one study found
no link between occurrence of reactive amyloidosis and HLA antigens of 60 Finnish RA patients
(Tiitinen et al., 1992). The authors suggested that in development of amyloidosis prolonged
inflammation may play a more important role than genetic factors. Findings regarding mortality due
to reactive amyloidosis are too variable to draw any definite conclusions. Additional studies are
thus needed to confirm whether Finnish RA patients are more susceptible to amyloidosis than other
populations.
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No significant sex-related differences existed in mortality due to amyloidosis; amyloidosis
caused death in 71 females (10%) and 18 males (7%) (p=0.196). This observation is similar to that
of a Finnish population-based study, in which mortality due to amyloidosis was higher, albeit not
significantly, in females than in males (6.2% vs. 4.8%) (Myllykangas-Luosujärvi et al., 1999).
Patients died frequently due to malignancies originating from the lungs and the lymphatic
system (Table 15). This is in agreement with studies showing RA patients to be at risk for death
from LPMs (Laakso et al., 1986b; Symmons et al., 1998; Thomas et al., 2003; Sihvonen et al.,
2004a) and lung cancer (Thomas et al., 2003). The RA patients here died frequently due to
malignancies of the GI tract, inconsistent with studies reporting RA patients’ reduced mortality due
to GI malignancies (Laakso et al., 1986b, Thomas et al., 2003). Breast cancer was also a frequent
CoD.
Table 15. Deaths caused by various malignancies from 1971 to 1991 in Study population A
Multiple cause of death; site Total
n (%)
Lung 34 (4)
Gastrointestinal tracta 19 (2)
Lymphoproliferative













Thyroid gland 1 (0.1)
Other 6 (0.6)
Total 126 (13)
aoesophagus, stomach, colon, or any combination of these; bincluding ovarian, uterus, and cervical cancers, or any combination of these (unpublished
data).
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6.1.2 Changes in causes of death over time
From 1971 to 1991, deaths caused by RA declined (Figure 6; p-value for linearity<0.001), in
accordance with other authors’ observations of a decline in deaths caused by RA from 1950 to 1981
(Wicks et al., 1988) and from the 1970s to the 1990s (Ziade et al., 2008). No significant change was
detected in deaths due to amyloidosis over the 21-year period, although renal deaths declined
(Figure 7; p-value for linearity=0.010). Because reactive amyloidosis frequently manifests as renal
failure, this might merely reflect deaths caused by amyloidosis. However, withdrawal of phenacetin
in Finland in 1965 may contribute to the decline in renal deaths. The banning of phenacetin has
been shown to be followed by a decrease in mortality caused by renal disorders (Sillanpää et al.,
1982). No significant changes occurred from 1971 to 1991 in deaths due to other disorders.
Calendar years
































Figure 6. Sex- and age-adjusted deaths caused by rheumatoid arthritis with 95% confidence
intervals. Multiple causes of death.
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Figure 7. Sex- and age-adjusted deaths caused by renal disorders with 95% confidence intervals. Multiple
causes of death.
6.1.3 Causes of death determined clinically and at autopsy
Between autopsied RA patients (n=513) and those not autopsied (n=447), no significant differences
emerged in CVDs in an analysis of underlying CoD (45% vs. 47%; p=0.539), immediate CoD (50%
vs. 46%; p=0.190), or multiple CoDs (both 61%; p=0.985). Similarly, no significant differences
between these patient groups appeared in multiple CoD analysis of infectious, malignant,
respiratory, or haematological diseases (data not shown). These findings suggest that, with respect
to these disorders, non-autopsy and autopsy RA populations may be similar. However, compared
with those not autopsied, autopsied patients died more frequently of CHD (40% vs. 33%; p=0.026)
and GI disorders (13% vs. 4%; p<0.001), but less frequently of RA (38% vs. 52%; p<0.001),
endocrinological diseases (2% vs. 7%; p<0.001), cerebrovascular diseases (10% vs. 14%; p=0.037)
(unpublished data), and renal diseases (6% vs. 9%; p=0.049).
In non-autopsied patients, the explanation for more frequent deaths due to RA, endocrinological
diseases, cerebrovascular diseases, and renal diseases is unclear. However, in cerebrovascular and
renal diseases, the difference between autopsied and non-autopsied individuals was barely
significant. Diabetes constituted the majority of endocrinological diseases (Table 13). Diabetes and
RA are both clinical diagnoses, a fact that may contribute to these observations. Clinicians had
likely regarded autopsy as unnecessary in cases of severe RA or severe diabetes. Compared with
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autopsied RA patients, non-autopsied patients seemed to have more unspecific CoDs, such as renal
failure (4% vs. 8%; p=0.002) and heart failure (3% vs. 11%; p<0.001). Furthermore, renal failure in
non-autopsied patients constituted the majority of renal deaths. In non-autopsied patients, renal
disease was detected in 40 patients, 37 of whom had renal failure. However, renal failure merely
represents a common end-stage for various renal disorders and offers no information about the
underlying disorder. The same is true for heart failure.
Autopsied RA patients, compared with non-autopsied RA patients, more frequently had CHD as
a CoD. Furthermore, death rate due to GI disorders was 3-fold higher in autopsied patients. Several
explanations emerge for these findings. One explanation may be that autopsied patients who died
due to CHD and GI disorders were more often referred for autopsy. Another explanation may be
that these disorders remained undetected during the lifetime. This explanation is supported by
several observations. RA patients are susceptible to silent coronary deaths (Maradit-Kremers et al.,
2005b; Douglas et al., 2006). One study of 272 autopsied cases showed that even if the major
disease category of CVD is correct, the specific type of CVD may be incorrect (Kircher et al.,
1985). This seems to also have been reflected here. Autopsied and non-autopsied patients had
similar proportions of CVDs, but autopsied patients more frequently died due to CHD.
Furthermore, myocardial infarction in critically ill patients is often overlooked (Roosen et al., 2000;
Twigg et al., 2001; Perkins et al., 2003). With respect to GI disorders, the RA patients here likely
were frequently on NSAIDs, which promote GI complications. One explanation for more frequent
GI-related deaths in autopsied patients may be that RA patients are susceptible to serious GI
complications, which frequently occur without warning signs or symptoms (Singh, 1998). In
addition, GI haemorrhage in critically ill patients may be overlooked by the treating physician
(Roosen et al., 2000).
Death caused by amyloidosis was found in similar proportions in both autopsied RA patients
and those not autopsied (10% vs. 9%; p=0.420). This may indicate that the autopsy and non-autopsy
populations are similar. On the other hand, it is also possible that amyloid deaths in those without
autopsy may have gone undiscovered. RA-associated peri- or myocarditis or both was observed
more frequently in autopsied patients (six patients) than in those not autopsied (one patient),
although the difference was insignificant (p=0.129). It is also noteworthy that deaths caused by
medullar compression after cervical subluxation were only detected in autopsied patients (three
patients). In autopsied patients, other RA-associated complications were Felty’s syndrome (three
patients), pulmonary fibrosis (two patients), renal failure, pleuritis, and extra-articular feature not
specified (one patient each). In those not autopsied, such complications were vasculitis, pulmonary
fibrosis, tetraparesis as a consequence of medullar compression in region CIV-V after atlanto-
occipital fusion operation, and renal failure (one patient each).
52
6.2 Study population B
Age at death in Study population B increased between 1952 and 1991, the mean age at death + SD
being 70 + 9 years. As in the general population, the mean age at death increased over the 40 years
in females from 66 to 77 years (p-value for linear trend<0.001) and in males from 58 to 73 years (p-
value for linear trend=0.001) (Figure 8).
Figure 8. Age of female and male rheumatoid arthritis patients at death compared with that of the Finnish
general population at ten-year intervals. Open circles show rheumatoid arthritis patients and box plots show
the whole Finnish population. The box presents median (horizontal line in the box) and interquartile range
(IQR). Whiskers show the 5th and 95th percentiles (unpublished data)
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6.2.1 Causes of death
Autopsied RA patients died most frequently due to RA, CVDs, and infections (Table 16).
When multiple CoDs were analysed, RA caused death in 255 patients (69%). As an
immediate CoD, RA was found in only 21 patients (6%).
Table 16. Causes of death determined at autopsy from 1952 to 1991 in Study population B
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Respiratory disorders 36 (10) 24 (7) 0.101  9 (2) 9 (2) 0.995
GI=gastrointestinal; RA=rheumatoid arthritis; aincluding cardiac, cerebrovascular, and vascular diseases; bunpublished data; cat any site.
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Compared with autopsied non-RA patients, autopsied RA patients died in a multiple CoD
analysis more frequently due to infections and renal disorders, but less frequently due to
CVDs, malignancies, and endocrinological disorders. The use of proportional CoD
statistics may cause bias because the proportion of deaths from RA was high. To
overcome this effect a separate analysis of immediate CoD alone was conducted. As a
result, no significant difference was detected between RA and non-RA patients in deaths
caused by endocrinological disorders and malignancies. However, RA patients died in an
analysis of immediate CoD less frequently of CVDs (including CHD and cerebrovascular
diseases), but more frequently of infections and renal disorders (Table 16). Excess renal
deaths in RA patients may be associated with use of NSAIDs, such as phenacetin, or with
reactive amyloidosis.
CVD was an underlying CoD in 219 non-RA subjects (59%) and in 128 RA subjects
(35%) (p<0.001); the latter figure is close to that of others (Allebeck, 1982; Symmons et
al., 1998; Sihvonen et al., 2004a) (Table 14). One explanation for less frequent
cardiovascular deaths in RA patients may be that the non-RA patient population selection
process was biased. This explanation is supported by the fact that Kivelä Hospital was an
acute care hospital responsible for specialized health care of such internal diseases as
CVDs and diabetes. CHD was an underlying CoD in 101 non-RA patients (27%) and 64
RA patients (17%; p=0.001) (unpublished data). The proportion of coronary deaths in RA
patients was lower than in other reports covering later periods (Wållberg-Jonsson et al.,
1997; Kvalvik et al., 2000; Young et al., 2007). The explanation for this lower occurrence
of coronary deaths in the study here is unclear. I can only speculate that this difference
may have arisen from coronary deaths being less frequent at the beginning of this study,
which covered the period from 1952 to 1991.
Of patients in Study population B, RA as a CoD in multiple cause analysis and in
underlying CoD analysis was observed, in 69% and 31% of patients, respectively, the
latter figure higher than that reported in several other studies (Allebeck et al., 1981;
Allebeck, 1982; Wållberg-Jonsson et al., 1997; Symmons et al., 1998; Kvalvik et al.,
2000; Sihvonen et al., 2004a; Young et al., 2007) (Table 14). The reason behind the high
proportion of deaths due to RA at autopsy is obscure. One explanation is that the higher
rate of RA deaths may merely reflect a more severe RA course in patients dying during the
first two decades of the study (1952-71) compared with the later periods (1972-91)
(Allebeck, 1982; Wållberg-Jonsson et al., 1997; Symmons et al., 1998; Kvalvik et al.,
2000; Sihvonen et al., 2004a; Young et al., 2007). The course of disease activity in RA
patients has been suggested to have become milder (Welsing et al., 2005). This is
supported by the finding of deaths caused by RA declining. However, no evidence
indicates that all-cause mortality in RA patients has declined (Tables 1 and 2). Another
explanation is that autopsy may reveal RA-related deaths that would otherwise have gone
undetected. Studies have shown that the contribution of RA to mortality may be
underestimated (Allebeck et al., 1981), especially when the underlying CoD is malignancy
or CVD (Laakso et al., 1986c).
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Of the RA patients in Study population B, amyloidosis caused death in approximately
10%. Other RA-associated complications were very uncommon. These included acute
medullar compression of the cervical spine (three patients), Felty’s syndrome (two
patients), vasculitis, myo- or pericarditis or both, rheumatic lung involvement,
agranulocytosis with splenomegaly, and chronic laryngitis (one patient each).
In Study population B, amyloidosis caused death in 22 (8%) female and in 13 (15%)
male (p=0.060) RA patients. This indicates no sex-related difference in RA patients in
amyloid deaths. This finding of no gender difference is contrary to one hospital-based 10-
year follow-up study reporting more females (12.8% vs. 5.8%) to have died from
amyloidosis (Laakso et al., 1986a). However, those findings may be biased, because only
RA patients aged 40 years or over were included in that study. Furthermore, autopsy, the
gold standard for determination of CoD (Goldman et al., 1983; Welsh and Kaplan, 1998),
was performed in only one-third of the RA cases in that Finnish study.
In Study population B with no systematic cervical spine examination, only
approximately 1% of the RA patients died due to medullar compression of the cervical
spine, close to the findings in 81 RA patients routinely autopsied (1.2%) (Suzuki et al.,
1994). These figures are both, however, much lower than that reported in a study of 104
RA patients with their cervical spines autopsied systematically (10%) (Mikulowski et al.,
1975).
Of the RA patients, approximately one-third, in analysis of immediate or multiple
CoDs, died due to infections. Of infections, the majority were attributed to infections of
the respiratory tract and the urinary tract (Table 16). As an underlying CoD, infection was
observed in 38 autopsied RA patients (10%), close to the observation from a hospital-
based follow-up study covering the period 1977 to 1992 (Kvalvik et al., 2000). Autopsy-
based studies, comprising 81 patients or fewer, have reported proportions 2-fold higher
than that found in the current autopsy study (Mutru et al., 1976; Suzuki et al., 1994).
Compared with the non-RA patients, the RA patients here died significantly more
frequently from infections (Table 16). Respiratory infections were as frequent in RA
patients as in non-RA patients (22% vs. 22%; p=0.969). However, the proportion of deaths
caused by urinary tract infections in RA patients, compared with non-RA cases, was
almost 3-fold higher (8% vs. 3%; p<0.001), in accordance with the findings in a 10-year
follow-up study of 1000 RA patients reporting more deaths due to urinary tract infections
in female RA patients than in non-RA females (Laakso et al., 1986a).
RA patients died more frequently than the reference cases due to renal disorders (Table
16), resembling the findings of others (Symmons et al., 1998; Thomas et al., 2003). This
overpresentation of renal disorders in RA may be linked to use of NSAIDs or reactive
amyloidosis. GI deaths were not more frequent in RA patients (Table 16), contrary to the
observations of others (Vandenbroucke et al., 1984; Sihvonen et al., 2004a). This may be
explained by Kivelä Hospital having no surgical facilities.
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RA patients died significantly less frequently than non-RA patients due to
malignancies (Table 17, unpublished data), in parallel with a 35-year follow-up study
(Wolfe et al., 1994). However, the RA patients died significantly more frequently of
lymphoma (Table 17), consistent with Symmons et al (1998) and Sihvonen et al (2004a).
As in a 20-year study reporting increased risk in RA patients dying of lung cancer
(Thomas et al., 2003), lung cancer was more common, albeit non-significantly, in the RA
patients (Table 17). The current study suggested no reduced mortality due to malignancies
of the GI tract, contrary to some other authors (Laakso et al., 1986b; Thomas et al., 2003).
Autopsied RA patients died less frequently than non-RA patients of breast cancer and
gynaecological cancers. Some studies have reported findings similar to ours. In one
hospital-based study comprising 1165 RA patients followed for 8 years, breast cancer
caused death in three RA patients, while the expected number was 5.2, a non-significant
finding (Allebeck, 1982). In another hospital-based study on 1000 RA patients and their
controls followed for 10 years, breast cancer was a CoD in only one RA patient and six
controls (Laakso et al., 1986b). In that same study, uterine or ovarian cancer was a CoD in
three RA patients and six controls. In a study on 81 autopsied RA patients and 243
controls, ovarian cancer caused death in 2% of RA patients and 11% of controls (Suzuki et
al., 1994). ASA, frequently used by RA patients in this study, has been associated in large
epidemiological studies with reduced risk of breast cancer (Schreinemachers and Everson,
1994; Johnson et al., 2002). ASA has also shown beneficial effects with respect to
mortality. In one large prospective population-based study on postmenopausal women, use
of ASA was linked to decreased overall mortality as well as to decreased mortality from
malignancies (Bardia et al., 2007). However, as the numbers of patients have been small,
these results suggesting reduced mortality risk of breast cancer and gynaecological
malignancy in RA should be analysed with caution.
57
Table 17. Deaths caused by various malignancies from 1952 to 1991 in Study population B














Gastrointestinal tracta 7 (1.9) 8 (2.2) 0.798
Gallbladder 3 (0.8) 2 (0.5) 0.686
Liver 2 (0.5) 6 (1.6) 0.286
Brain 2 (0.5) 5 (1.4) 0.451
Pancreas 2 (0.5) 2 (0.5) 1.000
Melanoma 2 (0.5) 1 (0.3) 0.624
Breast 1 (0.3) 8 (2.2) 0.038
Gynaecologicalb 0 (0) 7 (1.9) 0.015
Kidney 0 (0) 3 (0.8) 0.249
Prostate-testis 0 (0) 1 (0.3) 1.000
Other 3 (0.8) 10 (2.7) 0.051
Total 43 (12) 68 (18) 0.011
aesophagus, stomach, colon, or any combination of these (unpublished data); bincluding ovarian, uterus, and cervical cancer, or any
combination of these.
6.2.2 Changes in causes of death over time
In autopsied RA patients, deaths caused by CHD increased throughout the 40-year study
period (p-value for linearity=0.021), but coronary deaths in non-RA cases showed a
decline, starting in the 1970s (p-value for linearity=0.13) (Figure 9). The observation in
the RA patients here is contrary to one study on American RA patients reporting a decline
in mortality during 1980 to 1997 due to acute myocardial infarction (Krishnan et al.,
2004). However, one large meta-analysis of cardiovascular mortality in RA covering the
period until 2005 reported that the risk of cardiovascular death was higher in RA patients
enrolled after 1987 than in those enrolled earlier (Avina-Zubieta et al., 2008). Other
studies, covering the 1960s to the 1990s, have observed no significant changes in
mortality due to specific causes (Suzuki et al., 1994; Björnådal et al., 2002).
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Figure 9. Sex- and age-adjusted coronary deaths with 95% confidence intervals according non-
rheumatoid and rheumatoid arthritis patients. Multiple causes of death.
As the proportional decrease in mortality due to RA might contribute to the frequency of
other CoDs, immediate coronary deaths as well as atherosclerotic findings in coronary
arteries at autopsy for the period 1952 to 1991 were analysed separately. In the analysis of
immediate CoD, RA patients showed an increasing trend, with only a slight decline at the
end of the study in coronary deaths (p-value for linearity during the whole study
period<0.001), while a steeper and earlier decline occurred after an increase in non-RA
patients (p-value for linearity during the whole study period=0.009) (data not shown).
 Between the two patient groups, no significant differences emerged during the
40 year period in either immediate (data not shown) or all coronary deaths (Figure 9).
At autopsy, atherosclerotic findings in coronary arteries were detected in 221 (46%)
RA patients and in 259 (54%) non-RA patients (p=0.004; unpublished data). Over the 40
years, autopsy revealed in RA patients (p-value for linearity=0.73) and in their controls (p-





































Figure 10. Sex- and age-adjusted coronary atherosclerosis at autopsy with 95% confidence
intervals according to non-rheumatoid (n=362) and rheumatoid arthritis patients (n=363)
(unpublished data).
Several explanations can be tendered for the increasing trend in coronary deaths in RA
patients. One explanation is RA medication. Effective suppression of active inflammation
in RA is suggested to prevent development of atherosclerosis (Van Doornum et al., 2002).
The RA patients in the current study may have been treated for their RA less actively than
American RA patients, 11-37% of whom used MTX (Krishnan et al., 2004). Of the RA
patients here, approximately 80% used DMARDs, including cytostatics other than MTX,
i.e. CYC (seven patients) and AZA (three patients). However, DMARD duration was
short and likely had not been started early in the disease course. On the other hand, the use
of GCs among American patients was slightly more common than among the patients
here. GCs were used by 60% of American patients and 50% of the patients in the present
study.
Another explanation may be that CHD in RA patients during the lifetime remained
undetected. Coronary deaths in RA patients, compared with non-RA patients, had been
diagnosed less accurately (Kappa reliability test; 0.33 vs. 0.46). Studies have shown RA
patients to be susceptible to silent coronary events (Maradit-Kremers et al., 2005b;
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Douglas et al., 2006). This observation may explain the inaccuracy in diagnosis of
coronary deaths in the RA patients here. However, the finding that subjects without RA
may have their CHD diagnosed more accurately might explain the decline in coronary
deaths in non-RA patients from the 1970s onwards, in line with a general trend in Finland
(Salonen et al., 1983). I can only speculate that because CHD was diagnosed in non-RA
patients more accurately they may have gained more benefit from the development of
diagnostic techniques and treatment of CHD.
For the increasing trend in coronary deaths in RA, a further explanation may be use of
non-ASA NSAIDs. Although some non-ASA NSAIDs, such as indomethacin, were in use
earlier (Jäättelä, 1981), various new NSAIDs were introduced in Finland in the late 1970s
(Martio, 1993). In RA patients, the frequent use of non-ASA NSAIDs, which has been
associated with an increased risk for cardiovascular events (Hermann and Ruschitzka,
2007), may also have affected the increasing trend of coronary deaths. Even the
concomitant use of low-dose ASA with non-ASA NSAIDs does not abrogate the
cardiovascular risk (Hermann and Ruschitzka, 2007). However, ASA may have played
some role in mortality from CHD in RA patients before the 1970s. An autopsy-based
study that showed RA patients to die less frequently than controls from CHD, a result
similar to the findings here, suggested ASA to have been a protective agent against
coronary events (Davis and Engleman, 1974).
While coronary deaths in non-RA patients showed a decline at the end of the study,
coronary deaths in RA patients were on the rise (Figure 10), with the exception of a minor
decline in the immediate coronary deaths at the very end of the study (data not shown).
Despite all of these changes in coronary deaths, atherosclerotic findings in coronary
arteries showed no significant changes over time. The explanation for the differences
between coronary deaths and coronary findings is obscure. One explanation for the
increasing trend in coronary atherosclerosis may be that statins did not become available
in Finland until the 1980s (Martikainen et al., 1996).
From 1952 to 1991, deaths caused by RA declined (p-value for linearity=0.002)
(Figure 11), resembling findings of other studies (Wicks et al., 1988; Ziade et al., 2008).
The French population-based study reported RA-related deaths from the 1970s to decline,
but then, particularly in the oldest patients, they showed a small rise starting in the mid-
1990s (Ziade et al., 2008).
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Figure 11. Sex- and age-adjusted deaths caused by rheumatoid arthritis with 95% confidence
intervals. Multiple causes of death.
No significant change occurred in Study population B in deaths caused by reactive
amyloidosis, CVDs, infections, malignancies, respiratory diseases, GI disorders,
endocrinological diseases, and haematological diseases (data not shown).
6.2.3 Contribution of autopsy to cause-of-death diagnoses
RA patients and their controls had one-third of their CoDs undetected before autopsy
(mean; 39% vs. 36%, respectively). This is similar to a study that showed that, of 108
autopsied geriatric patients, CoDs were undetected by the clinician in one-third (Zaitoun
and Fernandez, 1998). Between clinician-assessed CoD and that determined at autopsy by
a pathologist, RA patients had a lower agreement (Kappa reliability test; of various CoDs,
mean 0.35) than non-RA patients (mean 0.42). This was true especially with respect to
CVDs, including CHD. In the RA patients here, the most inaccurately diagnosed CoDs
were GI disorders, renal diseases, respiratory diseases, and CVDs, in this order. Deaths
caused by malignancies in RA patients and non-RA patients were diagnosed most
accurately, consistent with the findings of others in randomly selected autopsies from the
general population (Kircher et al., 1985)  and in consecutive autopsies at an adult hospital
(Sington and Cottrell, 2002) (Table 18).
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Table 18. Agreement between clinical causes of death and those determined at autopsy in
Study population B












Renal diseases 0.29 0.21
Gastrointestinal disorders 0.25 0.33
Respiratory diseases 0.30 0.24
Diabetesc 0.48 0.60
aKappa reliability test between the clinical cause of death and that made at autopsy (low agreement: < 0.40, medium: 0.40 – 0.75, high:
> 0.75); bincluding cardiac, cerebrovascular, and vascular diseases; cunpublished data.
6.2.4 Causes of death and medication
Between RA patients on DMARDs and those not on DMARDs, no significant difference
appeared in CoDs (data not shown). DMARDs, therefore, do not seem to predispose to or
prevent any CoDs. RA was a CoD in 59 patients on GCs (69%) and in 35 patients not on
GCs (47%) (p=0.005). Compared with those not on DMARDs, patients taking DMARDs
had a shortened lifespan (71 + 8 vs. 75 + 8 years; p=0.038), but no such difference was
observed with respect to GCs (data not shown). Evidently, these medications had been
used in patients with severe RA.
6.2.5 Detection rate of amyloid deposits
Systematic re-evaluation of autopsy tissue samples doubled the prevalence of amyloid
compared with routine autopsy, and tripled the prevalence compared with lifetime. Of the
RA patients autopsied from 1973 to 1991, amyloidosis had been diagnosed before autopsy
in only 16 (37%), resembling the findings of an autopsy-based series reporting pre-
mortem diagnosis of amyloidosis in one-third of their 18 patients with chronic
inflammatory disease (Wright and Calkins, 1981). In another study, pre-mortem detection
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rate of amyloidosis was as high as 81%, but the study was conducted at an amyloid clinic
(Browning et al., 1985). In an autopsy study from the 1950s, amyloidosis was diagnosed
before autopsy in less than one-tenth of cases with moderate to severe amyloid deposition
(Teilum and Lindahl, 1954).
At the original autopsies of the current study, Congo red staining to detect amyloid had
been performed on 93 of 369 RA patients (25%) and on 9 of 370 non-RA patients (2%).
Of those nine non-RA patients, five had suffered from an infection (three patients) or a
malignancy (two patients) during their lifetime. Other such disorders on autopsy referrals
included CHD, universal atherosclerosis, stroke, pulmonary embolism, and GI
haemorrhagia. Accordingly, amyloid was found in 67 RA patients (18%) and in 7 non-RA
patients (2%) (p<0.001). Of those non-RA cases in multiple CoD analysis, death was
caused by CVDs (nine patients), infection or pulmonary disease (three patients both), GI
disorder (two patients), and haematological disorder (one patient).
Autopsy tissue samples of these 739 patients were available for systematic re-
evaluation for 328 RA patients (89%) and for 336 non-RA patients (91%) doubling the
amyloid detection rate in both RA (97 patients; 30%) and non-RA patients (12 patients;
4%). The number of non-RA patients with cardiac amyloidosis (six patients) was 2-fold
higher than the number of those with renal amyloidosis (three patients). In the RA
patients, amyloid found at re-evaluation was as frequent in the kidneys as in the heart
(Table 19).




Other organs 48/194 (25)
  Liver 14
   Spleen 13
   Thyroid gland 8
   Synovia/joint 8
Total 97/328 (30)
n/N=amyloid-positive finding/tissue samples examined.
The systematic re-evaluation of autopsy tissue samples revealed no sex-related difference
in amyloid prevalence. Amyloid was detected in 74 females (30%) and in 23 males (30%).
This is contrary to some reports suggesting males to be at higher risk of developing
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reactive amyloidosis (Cohen and Comerford, 1968; Gertz and Kyle, 1991; Wiland et al.,
2004). However, these studies comprised only a few patients.
RA patients with amyloid at re-evaluation, compared to amyloid-negative RA patients,
had had a significantly higher erythrocyte sedimentation rate (ESR) and lower
haemoglobin (HB), in accordance with a 15-year follow-up study of RF-positive RA
patients (Tiitinen et al., 1993). These laboratory parameters were regarded as reflecting
the inflammatory level, although they may also appear in renal failure. The amyloid-
positive patients here had longer RA duration, in parallel with the findings of others
(Boers et al., 1987; Kobayashi et al., 1996; Kuroda et al., 2002; Wiland et al., 2004). The
amyloid-positive RA patients were also more disabled, consistent with other studies in
which amyloid-positive RA patients had had more joint erosions (Wiland et al., 2004) or
worse functional status (Kobayashi et al., 1996). Clinical manifestations associated with
amyloidosis, such as proteinuria or renal failure or both, occurred in only about half of the
amyloid-positive RA patients (Table 20). Between amyloid-positive RA patients and those
with amyloid-negative findings, no significant difference was detected in the proportion of
RA patients on DMARDs or GCs or both (data not shown). Neither were there any
significant differences between patient groups in frequency of extra-articular
manifestation, RF positivity, or abnormal ECG findings (data not shown).
Table 20. Factors associated with amyloida in autopsied RA patients
Amyloid + Amyloid – p-value
ESR (mm/h); mean+SD 69 + 26 51 + 21 <0.001
HB (g/l); mean+SD 107 + 15 122 + 14 <0.001
Proteinuria; n (%) 24 (56) 9 (9) <0.001
Renal failure + renal amyloidosis; n (%) 43 (56) 17 (9) <0.001
Heart failure + cardiac amyloidosis; n (%) 26 (41) 66 (40) 0.958
Steinbrocker class III – IV; n (%) 44 (98) 78 (77) 0.002
Severe joint destructionb; n (%) 31 (32) 49 (21) 0.039
Duration of RA (years); mean+SD 21 + 12 16 + 11 0.040
Age at death (years); mean+SD 69 + 10 71+ 8 0.052
  Age at death with or without renal amyloidosis 69 + 9 71 + 8 0.051
  Age at death with or without cardiac amyloidosis 69 + 11 71+ 8 0.192
adiagnosed at re-examination of autopsy tissue samples; bradiographic changes typical of RA in hips, glenohumeral joints, or cervical
spine. Data on age at death and renal and heart failure were available between 1952 and 1991; the rest of the data between 1973 and
1991.
Amyloid in kidney samples was of type AA in all but one of the 73 RA patients examined.
That RA patient without type AA amyloid had RA and pyelonephritis as a CoD.
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In the RA patients, the prevalence of amyloid in re-evaluated tissue samples showed
no significant change between 1952 and 1991 (p=0.792), contrary to one Finnish report by
Laiho et al (1999) that suggested a declining incidence of amyloidosis in patients with
inflammatory joint disease between 1987 and 1997. However, these two studies may not
be comparable. The studies comprised different study populations and covered different
time periods. The medication of the RA patients in the current study may have been less
effective because of the earlier period covered. However, medication in the study by Laiho
et al (1999) went unreported. Furthermore, their survey of tissue samples was not
systematic and they used fine-needle aspiration of subcutaneous fat, which may be less
sensitive than rectal (Klemi et al., 1987; Dhillon et al., 1989) or gastroduodenal biopsies
(Kuroda et al., 2002).  In addition, their number of samples taken decreased over time.
Unlike Laiho et al (1999), who reported new cases with amyloid-positive findings from a
cross-sectional study of living patients, the current study reports the lifetime burden of
inflammation in RA patients in the final stage of their disease.
66
7. General discussion
As it appears to be proven that mortality is increased in RA patients, the aim of this study
was to evaluate determinants of mortality over a long period. Because diagnosis of CoD
may be inaccurate without autopsy, this study aimed to clarify the contribution of autopsy
to the diagnosis of CoD. Furthermore, the study investigated the contribution of RA
medication to CoDs and the detection rate of amyloidosis.
CoDs in a large RA population were investigated over a long period. In the literature,
only a few RA mortality studies have reported mortality changes in specific CoDs over
time. This study is strengthened by CoDs being examined in each RA patient treated at
Kivelä Municipal Hospital between 1971 and 1991 who died during that period (Study
population A). Kivelä Hospital was responsible for primary to tertiary care of all RA
patients in the Helsinki area. Furthermore, RA patients were treated by rheumatologists,
and standard practice was to start any DMARD in the hospital ward. Thus, the RA
population in Study population A is likely to be representative of mild to severe RA.
This study focused on CoDs determined at autopsy. CoDs were studied in RA patients
consecutively autopsied from 1952 to 1991, with patients having no rheumatic disease
autopsied at the same hospital serving as reference cases (Study population B). The study
emphasizes the role of autopsy in determination of CoD. Based on the findings here,
autopsy in RA patients is important, especially in the determination of cardiovascular
deaths. In the literature, no studies are available on the role of autopsy in CoD
determination in RA patients. Only a few studies exist that report on CoDs in autopsied
RA patients (Davis and Engleman, 1974; Mutru et al., 1976; Suzuki et al., 1994).
However, none of these have investigated the accuracy of CoD determination.
All patients deceased between 1952 and 1991 had not undergone autopsy (Study
population B) which is one limitation of this study. This may cause some bias in the
patient population. However, the potential bias is reduced by the autopsy rate being high
(67%). Furthermore, autopsies over the 40 years had been performed by only a few
pathologists.
Autopsy rates have constantly declined over time. In the 1960s, the hospital autopsy
rate in Europe and in the USA was approximately 60%, but today it is 10% or less
(Roulson et al., 2005). Similarly, the autopsy rate at Kivelä Hospital declined. Because of
this decline, the end for the study was set at 1991. The aim in the current study was to
collect as many RA patients as possible (Study population B) so that RA patients
autopsied each year would represent as closely as possible all RA patients who had died
that particular year.
Most RA mortality studies have been based on official death certificates, but only a
few have been based on analysis of autopsy reports (Davis and Engleman, 1974; Mutru et
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al., 1976; Suzuki et al., 1994), as the current study. However, autopsy is regarded as the
gold standard for determination of CoD (Goldman et al., 1983; Welsh and Kaplan, 1998).
The discrepancy rate between clinical and autopsy-based diagnoses has been high
(Goldman et al., 1983; Stevanovic et al., 1986; Landefeld et al., 1988; Zarbo et al., 1999;
Roosen et al., 2000; Twigg et al., 2001; Perkins et al., 2003; Combes et al., 2004). New
diagnostic techniques, such as ultrasound, computerized tomography, and radionuclide
scans, have not reduced the discrepancy rate (Kirch and Schafii, 1996). Furthermore, the
clinician's certainty about the diagnosis before autopsy seems to correlate poorly with the
final diagnosis determined at autopsy (Cameron et al., 1980; Podbregar et al., 2001).
Most RA mortality studies report only underlying CoD or sometimes underlying and
contributory CoDs. However, multiple CoD analysis, used in this study, is recommended
in evaluating mortality caused by chronic diseases such as RA (Ziade et al., 2008). An
analysis based solely on underlying CoD may underestimate contribution of a disease to
mortality (Redelings et al., 2006). Reporting both underlying CoD and multiple CoDs is
therefore recommended (Redelings et al., 2006). Furthermore, according to WHO
guidelines, reactive amyloidosis should not be recorded as the underlying CoD. Thus, if
only underlying CoD is analysed, information about reactive amyloidosis may remain
undetected. In addition, use of the ICD coding system may result in losing information
about infectious CoDs because several infections are recorded under the organ system that
they affect. For that reason, this study was based on diagnoses of CoDs in which
infections were classified under their own heading.
To the best of my knowledge, the current study is the first series on the detection rate
of amyloidosis at routine autopsy, and one of the few studies reporting lifetime detection
rate of amyloidosis. One limitation here is that lifetime detection rate of amyloidosis was
only available from 1973 onwards, with 95% of medical records before this having been
destroyed. On the other hand, tissue samples taken during routine autopsies were available
for as many as 90% of patients. Furthermore, the type of amyloidosis was determined in
kidney samples, which confirmed that all but one RA patient had AA amyloidosis.
Only infrequently may RA subside and end up in remission; usually, it leads to joint
deformities, functional disability, and premature death. RA medication is nowadays
started early in the disease course, and the treatment strategies have become more
effective over time. Mortality in RA patients has, however, remained high (Table 1). The
mortality gap between RA patients and the general population appears to have become
even wider (Gonzalez et al., 2007). More attention should thus be paid to mortality,
especially determinants of mortality, as an outcome measure in RA.
In RA patients, CVD is the major determinant of mortality (Allebeck et al., 1981;
Allebeck, 1982; Wållberg-Jonsson et al., 1997; Symmons et al., 1998; Björnådal et al.,
2002; Goodson et al., 2002; Mikuls et al., 2002; Sihvonen et al., 2004a; Goodson et al.,
2005), reflected also in the current study. Only a few studies have reported low
proportions of cardiovascular deaths in RA patients. In these studies, cardiovascular death
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occurred in 21% of Spanish RA patients (Martinez et al., 2001) and 17% of Japanese RA
patients (Suzuki et al., 1994). However, several other series have reported higher
cardiovascular death rates, varying from 31% to 53% (Mutru et al., 1976; Allebeck et al.,
1981; Allebeck, 1982; Wållberg-Jonsson et al., 1997; Symmons et al., 1998; Sihvonen et
al., 2004a; Young et al., 2007) (Table 14). Because many of these studies (Wållberg-
Jonsson et al., 1997; Symmons et al., 1998; Sihvonen et al., 2004a; Young et al., 2007)
used only underlying CoDs in their analyses, the proportion of RA patients dying of CVDs
may be even higher.
RA patients are at increased risk for dying of CHD, which constitutes the majority of
cardiovascular deaths. Mortality risk for CHD seems to be more evident in females, in
whom the risk, compared with the general population, has been 2-fold (Thomas et al.,
2003; Goodson et al., 2005). Furthermore, congestive heart failure, rather than CHD, has
been proposed to be an important contributor to the excess mortality in RA (Nicola et al.,
2006).
One primary care cohort of recent-onset inflammatory polyarthritis, representing early
RA, demonstrated that SMR for cardiovascular death is the highest in patients seropositive
for RF who were under 55 years of age at onset of arthritis (Naz et al., 2008). The authors
recommended that such patients warrant particular attention in terms of disease and risk
factor modification. Although the relative risk for cardiovascular events is higher in young
adults, the difference in absolute terms, compared with the general population, is highest
in older adults (Solomon et al., 2006). Therefore, both young and old RA patients are at
increased risk for cardiovascular events, and both of these subgroups should be included
when considering preventive strategies (Solomon et al., 2006).
The reason for increased cardiovascular mortality in RA is likely to be multi-factorial.
RA patients not only have an increased risk for developing CHD, but also a higher risk for
worse outcome than the general population (Södergren et al., 2007). Systemic
inflammation seems to play, via several mediating factors, such as dyslipidaemia, insulin
resistance, and endothelial dysfunction, an important role in premature atherogenesis (Van
Doornum et al., 2002; Snow and Mikuls, 2005). Accelerated atherosclerosis, reported
even in pre-menopausal female RA patients (Pahor et al., 2006), has been proposed to be
an extra-articular feature of RA (Van Doornum et al., 2002). RA patients appear to
receive, with respect to various diseases, suboptimal health maintenance and preventive
care services (Kremers et al., 2003). This may be one factor contributing in these patients
to increased cardiovascular mortality. Furthermore, one study has shown that, despite
cardiovascular deaths being increased in RA patients, no difference exists, compared with
the general population, in CVD admission rates (Goodson et al., 2005). Another factor
may be susceptibility to silent coronary events (Maradit-Kremers et al., 2005b; Douglas et
al., 2006), as reflected also in this study in which the diagnosis of cardiovascular death in
RA patients, compared with non-RA patients, was less accurate. Thus, special attention
should be paid to diagnosis and treatment of CVDs in RA patients.
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The cardiovascular risk in RA patients has been shown to be comparable with that of
patients with diabetes mellitus (van Halm et al., 2008). RA patients with severe disease
are especially at risk for cardiovascular death, which is predicted by constantly active
disease (Wållberg-Jonsson et al., 1999; Goodson et al., 2005; Maradit-Kremers et al.,
2005a), by seropositivity for RF (Goodson et al., 2002, Maradit-Kremers et al., 2005a;
Gonzalez et al., 2008b), by functional disability (Farragher et al., 2007), and by extra-
articular features, such as rheumatic nodules (Maradit-Kremers et al., 2005a; Naz et al.,
2008), vasculitis, or rheumatic lung disease (Maradit-Kremers et al., 2005a). One study
suggested that the mechanisms responsible for cardiovascular morbidity and mortality
were different in RA patients than in subjects without RA (Aubry et al., 2007). In 41 RA
patients autopsied from 1985 to 2003, the authors observed, compared with 82 matched
non-RA controls, less histological evidence of atherosclerosis in coronary arteries, but
greater evidence of inflammation and instability, i.e. increased frequency of vulnerable
plaques. Thus, RA patients may be at higher risk for cardiovascular events than estimated
based on the degree of coronary atherosclerosis.
The current study observed in RA patients autopsied during the period from 1952 to
1991 no decline in coronary deaths, contrary to one study covering the period from the
1980s to the 1990s (Krishnan et al., 2004). One explanation for the decline in the latter
study may be the frequent use of MTX. The patients in the current study had not used
MTX. Use of MTX may increase levels of homocysteine, which is considered to be a risk
factor for CVD (Whittle and Hughes, 2004). Folates, i.e. folic or folinic acid, should be
supplemented to prevent hyperhomocysteinaemia (Whittle and Hughes, 2004). Chronic
inflammation in RA has been shown to be an independent risk factor for cardiovascular
mortality (Maradit-Kremers et al., 2005a). RA patients who respond to RA medication,
such as anti-TNF alpha therapy, have experienced a reduction in the incidence of
myocardial infarction (Dixon et al., 2007). Thus, effective anti-inflammatory treatment in
RA seems essential in reducing cardiovascular mortality.
Reports about lipid levels in RA patients are somewhat contradictory, but levels appear
to oscillate according to duration and severity of RA. Some studies have shown an inverse
association between CRP and high-density lipoprotein (HDL) cholesterol levels. In active
RA, concentrations of apolipoprotein A-1, a protein present on HDL cholesterol particles,
are decreased. Early untreated RA is associated with declines in HDL, with concomitant
elevations in low-density lipoprotein (LDL) and total cholesterol/HDL ratios. On the other
hand, a catabolic state in severe and advanced RA may lead to lowering in total
cholesterol, LDL, and HDL levels (Snow and Mikuls, 2005; Nurmohamed, 2007). Besides
beneficial effects on the lipid profile, statins also have additional properties (Calabro and
Yeh, 2005). One of these appears to be the ability to reduce inflammation (Calabro and
Yeh, 2005). A study on 116 RA patients showed that atorvastatin can mediate anti-
inflammatory effects (McCarey et al., 2004). That study reported the number of swollen
joints and inflammatory variables during atorvastatin therapy to decline. Thus, statins may
also have beneficial effects on RA activity.
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RA patients are, compared with those without RA, more likely to smoke, to be
physically inactive, and to have a higher body mass index (Brady et al., 2008). Thus,
efforts should be made to influence these life style cardiovascular risk factors. Cessation
of smoking is essential in reducing the risk for cardiovascular morbidity and mortality. To
prevent cardiovascular morbidity, RA patients should also be encouraged to exercise
regularly (Turesson and Matteson, 2007).
Dietary factors in RA patients are also important in reducing cardiovascular risk. The
Mediterranean diet has well-documented benefits on CVDs, and may also be advantagious
in RA management, given the increased risk of CVDs in RA patients (Choi, 2005). This
diet is characterized by less red meat and more fish, olive oil, poultry, and an abundance
of plant food (Choi, 2005). Especially, the n-3 fatty acids found in fish and fish oils are
beneficial in preventing CVDs and may also provide modest symptom alleviation in RA
(Stamp et al., 2005).
One study suggested that some traditional risk factors, i.e. male sex, history of CVD,
and even smoking, have in RA patients less impact than in the general population on
cardiovascular risk (Gonzalez et al., 2008a). The authors concluded that controlling solely
these traditional risk factors may not have the same impact on RA patients as expected
based on estimates from the general population. In another study, the risk of CVD in RA
patients was comparable with that of patients with diabetes mellitus (van Halm et al.,
2008). After adjustment for traditional cardiovascular risk factors, the chance of having
CVD was attenuated in these patients, but still significantly increased. Thus, traditional
cardiovascular risk factors only partly explained the high cardiovascular risk. Therefore,
controlling both inflammation and traditional risk factors in RA patients seems to be
important in cardiovascular risk management. It has been proposed that every RA patient
be screened for traditional cardiovascular risk factors (Nurmohamed, 2007). For RA
patients, similar treatment thresholds of lipids and blood pressure have been suggested as
those for patients with diabetes mellitus (Nurmohamed, 2007).
In RA patients, infections are important determinants of mortality (Allebeck, 1982;
Prior et al., 1984; Vandenbroucke et al., 1984; Mutru et al., 1985; Wolfe et al., 1994;
Symmons et al., 1998; Sokka et al., 1999; Mikuls et al., 2002; Sihvonen et al., 2004a), as
also shown here. The most common infectious deaths are due to infections of the
respiratory (Thomas et al., 2003; Sihvonen et al., 2004a) and urogenital (Vandenbroucke
et al., 1984) tract. Findings of the present study indicate that RA patients, compared with
those without RA, may be at similar risk for death due to respiratory infection, but at
higher risk for death by urinary tract infection. In the current study, medication for RA, i.e.
DMARDs and GCs, seemed not to predispose to or prevent any CoDs. In accordance with
this, risk of infections has not been associated with use of DMARDs (Coyne et al., 2007;
Lacaille et al., 2008). On the other hand, risk of infections does appear to be associated
with use of GCs (Coyne et al., 2007; Lacaille et al., 2008) and anti-TNF therapy
(Bongartz et al., 2006), neither of which was available to the RA patients here. The risk of
infectious death increases with RA duration (Symmons et al., 1998). Advanced age and
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male gender predict infections of the lower respiratory tract, which may have a fatal
outcome (Coyne et al., 2007). Active RA should be treated effectively, with careful
monitoring of infections, especially in elderly patients, males, and patients with advanced
RA.
RA patients have increased risk for dying of lymphoma (Symmons et al., 1998;
Sihvonen et al., 2004a), as also observed here. This risk seems to be associated with
inflammatory activity of RA, rather than RA medication (Bäcklund et al., 2006). Effective
treatment of RA is, therefore, essential in reducing risk of dying from lymphoproliferative
disorders. RA patients seem to die frequently of lung cancer (Thomas et al., 2003). The
increased risk of dying from lung cancer may be linked to tobacco smoking, which has a
causal connection to the development of RA (Heliövaara et al., 1993; Symmons et al.,
1997; Uhlig et al., 1999; Albano et al., 2001). Cessation of smoking is important in
reducing the risk of development of lung cancer as well as CHD.
Reactive amyloidosis is an important extra-articular manifestation contributing to
premature mortality (Lehtinen and Isomäki, 1991; Martinez et al., 2001; Sihvonen et al.,
2004a), reflected also in this study. The findings here indicate that amyloidosis frequently
remains undetected during the lifetime, in accordance with the findings of other authors
(Teilum and Lindahl, 1954; Wright and Calkins, 1981). Furthermore, amyloidosis may
remain undiscovered at routine autopsy, too. The impact of amyloidosis on mortality in
RA may thus be underestimated. Because even small amyloid deposits have been
associated with increased mortality (Kobayashi et al., 1996), amyloidosis should be
searched for actively. As demonstrated in the current study, male and female RA patients
seem to be at similar risk for development of amyloidosis. Only approximately half of the
amyloid-positive RA patients here had had renal failure or proteinuria. In addition, the
amyloid-positive RA patients had had, compared with those with amyloid-negative
findings, higher inflammatory activity, longer RA duration, and more disabling RA.
Therefore, the systematic search for amyloid is important not only in RA patients with
renal failure or proteinuria, but also in those with active, long-lasting, and disabling RA.
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8. Conclusions
Over this 40-year study period between 1952 and 1991, RA patients died most frequently
of CVD, RA, and infections. Deaths caused by RA seemed to be decreasing. The same
was not true for CVDs and infections. Despite advances in diagnostic technology, autopsy
remains an important tool in CoD determinations. In RA patients, CVDs, especially CHD,
may remain undetected during the lifetime. Active search and effective treatment of CHD,
as well as RA, are important in reducing cardiovascular mortality. Reactive amyloidosis
associated with RA is an important determinant of mortality. Prevalence of amyloid
deposits showed from 1952 to 1991 no significant change. In RA patients, amyloidosis
appears to be common, but is frequently undetected. Active search is essential for
detecting amyloidosis as early as possible. Amyloidosis should be searched for in RA
patients with proteinuria or renal failure or both, but also in those with active, long-lasting,
and disabling RA. Early detection of amyloid deposits enables the enhancement of
immunosuppressive medication, including biologicals, which may prevent development of
clinical manifestations and improve survival.
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